Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
  • A61K31/713—Double-stranded nucleic acids or oligonucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
  • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
  • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5123—Organic compounds, e.g. fats, sugars
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/53—DNA (RNA) vaccination
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55505—Inorganic adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

• the present disclosure relates generally to the field of pharmaceutical formulation, biologies and the manufacture of the same. More particularly, it concerns dry powder compositions that include, viruses, bacteria and polynucleotide molecules and methods of preparing powder compositions, such as by thin-film freezing.
• the present disclosure provides dry powder compositions comprising biologically active polynucleotide molecules and at least a first excipient, said dry powder having been produced by an ultra-rapid freezing process (URF), wherein the polynucleotide molecules retain substantial biological activity and/or have been stabilized by the URF process.
• URF ultra-rapid freezing process
• the polynucleotide molecules retain at least about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 40% or 50% of a biological activity compared to an equal amount of the polynucleotide molecule in solution prior to the URF process.
• the polynucleotide molecules have been stabilized such that at least 50% more of the molecules in the powder are undegraded relative the same polynucleotide molecules in a solution.
• the URF process comprises thin film freezing (TFF).
• the polynucleotide molecules are double-stranded molecules.
• the polynucleotide molecules are single-stranded molecules or a mix of double-stranded and single- stranded molecules.
• the polynucleotide molecules comprise siRNA, shRNA, dsRNA, ssRNA, mRNA, plasmid DNA and/or DNA oligonucleotides.
• the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than about 100 pm, 50 pm, 30 pm, 20 pm, 15 pm or 12 pm. In further aspects, the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of about 1 to 50 pm or 3 to 50 pm. In some aspects, the powder has a density of about 1.0 to g/cm 3 ; 2.0 1.4 to 1.9 g/cm 3 ; 1.4 to 1.9 g/cm 3 ; or 1.5 to 1.7 g/cm 3 .
• the powder has a surface area of about 2.0 to 8.5 m 2 /g; 2.0 to 7.5 m 2 /g; 3.0 to 7.5 m 2 /g; 2.0 to 5.0 m 2 /g; 2.5 to 4.5 m 2 /g; or 3.0 to 4.0 m 2 /g.
• the first excipient comprises a sugar, or sugar alcohol.
• the sugar is a disaccharide.
• first excipient comprises lactose, trehalose, sucrose, mannitol or sorbitol.
• the first excipient comprises at least about 50% of the powder by weight.
• the first excipient comprises from about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, to about 99.5% of the powder by weight.
• the first excipient comprises a sugar, or sugar alcohol.
• the dry powder compositions further comprise a pH buffering agent.
• the pH buffering agent comprises phosphate buffered saline (PBS), sodium acetate, or Mg 2+ storage (SM) buffer.
• the pharmaceutical dry powder composition has a water content of less than 20%, 15% or 10%.
• the pharmaceutical dry powder composition has a water content of from about 0.5% to 10%, 1% to 10%, 1.5% to 8% or 2% to 5%.
• the dry powder compositions further comprise at least a second, third and/or fourth excipient.
• the second, third and/or fourth excipient comprises an amino acid or protein.
• the second, third and/or fourth excipient comprises leucine or glycine.
• the second, third and/or fourth excipient comprises a polymer.
• the polymer comprises PEG, HPMC, PLGA, PVA, dextran, sodium alginate or PVP.
• the second, third and/or fourth comprises a sugar, or sugar alcohol.
• the powder comprises a mixture of two, three or more different sugars or sugar alcohols.
• the dry powder compositions further comprise a protein or a surfactant.
• the dry powder compositions further comprise casein, lactoferrin, Pluronic F68, Tyloxapol, or ammonium bicarbonate.
• the excipient comprises about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, to about 99.9% of the powder, such as from about 20 % w/w to about 99.9 % w/w of the powder.
• the biologically active polynucleotide molecule comprises a virus or a virus-like particle (VLP).
• the virus is a non-enveloped virus.
• the virus comprises an adeno-associated vims, adenovirus, an adeno- associated vims vector or an adenovims vector.
• the virus comprises bacteriophage.
• the bacteriophage infects S. aureus and/or P. aeruginosa.
• the bacteriophage particles comprise phage PEV2 or T7 phage.
• the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than 15 mht. In some aspects, the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than about 20 mht, 15 mht or 12 mht. In some aspects, the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of about 3 to 15 mht, 4 to 12 mht or 5 to 10 mht. In some aspects, at least about 20%, 25%, 30%, 35%, 40%, 45%, to about 50%, of the particles have a size of 1-5 mht, such as about 20%.
• the first excipient comprises a sugar or sugar alcohol. In further aspects, the first excipient comprises lactose, trehalose, sucrose, mannitol or sorbitol. In some aspects, the dry power further comprises an amino acid. In further aspects, the amino acid comprises leucine or glycine. In some aspects, the dry powder compositions comprise sucrose and leucine.
• sucrose and leucine are present in a ratio of from about 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 90:10, to about 95:5, such as from about 50:50 to about 95:5, about 60:40, from about 70:30 to about 90: 10; or from about 75:25 to about 80:20 (sucrose: leucine).
• the biologically active polynucleotide molecules comprise polynucleotide molecules encapsulated in lipid nanoparticles (LNPs).
• the biologically active polynucleotide molecule comprises a mRNA.
• the mRNA encodes an antigen.
• the dry powder composition further comprises an adjuvant.
• the adjuvant comprises aluminum salts, such as alum.
• the LNPs comprise ionizable lipids, phospholipids, cholesterol, lecithin and/or polyethylene) glycol (PEG)-lipid.
• the LNPs comprise cationic lipids; DOPE; DPPC; DSPC; DMPE-PEG; DMG-PEG; DSPE-PEG; Dlin-MC3-DMA; phospholipids; PEG- lipid and/or cholesterol.
• the LNPs have an average particle size of between about 25 nm and 1000 nm, 50 nm and 1000 nm; 50 nm and 600 nm, or 80 nm and 200nm.
• the first excipient comprises a sugar or sugar alcohol.
• the first excipient comprises lactose, trehalose, sucrose, mannitol or sorbitol.
• the dry powder compositions comprise from about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, to about 99% lactose, trehalose, sucrose, mannitol or sorbitol, such as from about 10% to about 99% or from about 50% to about 99.5% lactose, trehalose, sucrose, mannitol or sorbitol. In some aspects, the dry powder compositions comprise from about 80% to about 99% or from about 90% to about 99% sucrose.
• the biologically active polynucleotide molecule comprises siRNA.
• the LNPs comprise ionizable lipids, phospholipids, cholesterol, lecithin and/or poly-(ethylene) glycol (PEG)-lipid.
• the LNPs comprise lecithin, cholesterol and/or polyethylene glycol (2000)-hydrazone-stearic acid.
• the LNPs comprise cationic lipids.
• the LNPs have an average particle size of about 50 nm, about 75 nm, about 100 nm, about 125 nm, about 150 nm, about 175 nm, about 200 nm, about 225 nm, about 250 nm, about 275 nm, about 300 nm, about 325 nm, about 350 nm, about 375 nm, about 400 nm, about 425 nm, about 450 nm, about 475 nm, or about 500 nm, such as between about 50 nm and about 500 nm, about 75 nm and about 250 nm, about 80 nm and about 200 nm, about 90 nm and about 175nm, or about 100 nm and about 150 nm.
• the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than 15 ⁇ m . In some aspects, the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than about 20 ⁇ m , 15 ⁇ m or 12 ⁇ m . In further aspects, the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of about 3 to 15 ⁇ m , 4 to 12 ⁇ m or 5 to 10 ⁇ m . In some aspects, the powder has a mass median aerodynamic diameter between about 2 ⁇ m and 7 ⁇ m , 3 ⁇ m and 7 ⁇ m , 3 ⁇ m and 5 ⁇ m or 3.5 ⁇ m and 4.5 ⁇ m .
• the powder has a fine particle fraction (PPL) value of between about 25% and 60%, 30% and 50%, or 35% and 40%.
• the powder has a deposition in stages 4-7 in a Next Generation Impactor (NGI) of at least 10%, 15% or 20%.
• the powder has a deposition in stages 4-7 in a Next Generation Impactor (NGI) of between about 10% and 25%; 15% and 25%; 10% and 20% or 15% and 22%.
• the siRNA is less than 30 nucleotides in length.
• the siRNA is targeted to a human gene or a pathogen gene.
• the siRNA is targeted to TNF-a.
• the biologically active polynucleotide molecules comprise polynucleotide molecules complexed with chitosan.
• the chitosan is PEGylated.
• the biologically active polynucleotide molecules comprise DNA complexed with chitosan.
• the DNA molecules have been stabilized such that at least 50% more of the molecules in the powder are undegraded relative the same polynucleotide molecules in a solution.
• the DNA comprises plasmid DNA.
• the dry powder compositions comprise DNA encoding CRISPR/Cas9 elements complexed with chitosan.
• the dry powder compositions comprise DNA encoding a guide RNA complexed with chitosan.
• the chitosan complexes have an average size of about 100 nm to 2000 nm. In some aspects, the chitosan complexes have an average size of about 100 nm to 1000 nm; 150 nm to 800 nm or 200 nm to 800 nm.
• the first excipient comprises a sugar or sugar alcohol. In some aspects, the first excipient comprises lactose, trehalose, sucrose, mannitol or sorbitol.
• the dry powder compositions comprise about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, to about 90%, of a sugar or sugar alcohol, such as from about 5% to 90% of a sugar or sugar alcohol. In some aspects, the dry powder compositions comprise from about 10% to about 90%, from about 10% to about 70%, or from about 10% to about 50% of a trehalose, sucrose, and/or mannitol. In some aspects, the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than about 100 ⁇ m , 50 ⁇ m , 30 ⁇ m , 20 ⁇ m , 15 ⁇ m or 12 ⁇ m .
• the powder has a geometric particle size distribution Dv50, measured by dry Rodos method, of about 1 to 50 ⁇ m or 3 to 50 ⁇ m .
• the powder has a density of from about 1.0 to g/cm 3 to about 2.0 g/cm 3 , from about 1.4 to about 1.9 g/cm 3 , from about 1.4 to 1.9 g/cm 3 , or from about 1.5 to about 1.7 g/cm 3 .
• the powder has a surface area of about 2.0 to 8.5 m 2 /g; 2.0 to 7.5 m 2 /g; 3.0 to 7.5 m 2 /g; 2.0 to 5.0 m 2 /g; 2.5 to 4.5 m 2 /g; or 3.0 to 4.0 m 2 /g.
• the biologically active polynucleotide molecules comprise genomic material.
• the genomic material comprises bacterial, eukaryotic or archaeal genomic material.
• the powder comprises intact cells.
• the powder comprises living cells.
• the powder comprises intact bacterial, eukaryotic or archaeal cells.
• the powder comprises intact bacterial cells.
• the powder comprises living bacterial cells.
• the bacterial cells comprise gram negative bacteria.
• the bacterial cells comprise gram positive bacteria.
• the first excipient comprises a sugar or sugar alcohol.
• the first excipient comprises lactose, trehalose, sucrose, mannitol or sorbitol. In some aspects, the first excipient comprises sucrose. In some aspects, the powder is formulated for administration via inhalation. In some aspects, the powder is formulated for use with an inhaler.
• the present disclosure provides inhalers comprising a dry powder composition of the present disclosure.
• the inhaler is a fixed dose combination inhaler, a single dose dry powder inhaler, a multi-dose dry powder inhaler, multiunit dose dry powder inhaler, a metered dose inhaler, or a pressurized metered dose inhaler.
• the inhaler is a capsule-based inhaler.
• the inhaler is a low resistance inhaler.
• the inhaler is a high resistance inhaler.
• the inhaler is used with a flow rate from about 10 L/min to about 150 L/min. In some aspects, the flow rate is from about 20 L/min to about 100 L/min.
• the present disclosure provides methods of producing dry powder pharmaceutical composition
• methods of producing dry powder pharmaceutical composition comprising: (a) admixing an encapsulated biologically active polynucleotide molecule and a first excipient in a solvent to form a precursor solution; (b) depositing the precursor solution onto a surface at a temperature suitable to cause the solvent to freeze; and (c) removing the solvent to obtain the powder pharmaceutical composition.
• the methods further comprise: (d) disaggregating the powder pharmaceutical composition to reduce particle size and/or homogenize particle size.
• the precursor solution comprises water.
• the powder pharmaceutical composition has a water content of less than 20%, 15% or 10%.
• the powder pharmaceutical composition has a water content of about 0.5% to 10%, 1% to 10%, 1.5% to 8% or 2% to 5%.
• the temperature in step (b) is about -40°C to -180°C.
• the temperature in step (b) is about -50°C to -150°C, -50°C to -125°C, -55°C to -100°C or -65°C to -75°C.
• the precursor solution comprises a pH buffering agent.
• the precursor solution has a pH of about 6.0 to 8.0, 6.5 to 8.0, or 7.0 to 7.8. In some aspects, the precursor solution comprises about 0.1% to 30 %, 0.1% to 20%, 0.5% to 10% or 0.5% to 5% of the first excipient. In some aspects, the first excipient comprises a sugar or sugar alcohol. In some aspects, the precursor solution comprises about 0.1% to 5 %; 0.1% to 3% or 0.5% to 5% of a trehalose, sucrose and/or mannitol. In some aspects, the precursor solution has a solids content of about 0.1% to 50%. In some aspects, the precursor solution has a solids content of about 0.1% to 20%. In some aspects, the precursor solution has a solids content of at least about 0.25%. In some aspects, the precursor solution has a solids content of 0.25% to 10%; 0.5% to 10%; 1% to 5% or 2% to 5%.
• the biologically active polynucleotide molecule comprises virus or bacteriophage.
• the vims is a non-enveloped virus.
• the biologically active polynucleotide molecule comprises bacteriophage.
• the precursor solution comprises about lxlO 6 to lxlO 12 ; lxlO 6 to lxlO 11 ; lxlO 7 to lxlO 10 ; or5xl0 8 to lxlO 9 plaque forming units/ ml (PFU/mL) or focus forming units/ml (ffu/ml).
• the powder pharmaceutical composition has virus or bacteriophage particles that have lost less than 3.5 log titer (in plaque forming units/ ml (PFU/mL) or focus forming units/ml (ffu/ml)) as compared to the titer in the precursor solution. In some aspects, the powder pharmaceutical composition has virus or bacteriophage particles that have lost less than 3.0, 2.5, 2.0, 1.5, 1.0 or 0.5 log titer (in PFU/mLor FFU/ml) as compared to the titer in the precursor solution.
• the temperature in step (b) is about -40°C to -150°C, -50°C to - 125 °C, -55°C to -100°C or -65°C to -75°C. In some aspects, the temperature in step (b) is about -40°C to -100°C, -40°C to -90°C, -40°C to -80°C or -50°C to -75°C.
• the precursor solution comprises leucine. In some aspects, the precursor solution comprises leucine and sucrose.
• the precursor solution comprises sucrose and leucine in a ratio of about 50:50 to 95:5; 60:40; 70:30 to 90:10; or 75:25 to 80:20 (sucrose: leucine).
• the powder pharmaceutical composition has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than 15 pm. In some aspects, the powder pharmaceutical composition has a geometric particle size distribution Dv50, measured by dry Rodos method, of less than about 20 pm, 15 pm or 12 pm. In some aspects, at least 20% of the particles have a size of 1-5 pm. In some aspects, at least 25%, 30%, 35%, 40%, 45% or 50% of the particles have a size of 1-5 pm.
• the precursor solution comprises a pH buffering agent.
• the pH buffering agent is a PBS or SM buffer.
• the pH buffering agent is SM buffer and the precursor solution comprises trehalose and leucine.
• the biologically active polynucleotide molecules comprise polynucleotide molecules encapsulated in a lipid nanoparticles (LNPs).
• the biologically active polynucleotide molecule comprises a mRNA.
• the LNPs comprise ionizable lipids, phospholipids, cholesterol, lecithin and/or poly-(ethylene) glycol (PEG)-lipid.
• the LNPs have an average particle size of between about 25 nm and 1000 nm, 50 nm and 1000 nm; 50 nm and 600 nm, or 80 nm and 200 nm.
• the precursor solution comprises about 10% to 30% or 15% to 25% lactose, trehalose, sucrose, mannitol or sorbitol.
• the biologically active polynucleotide molecule comprises siRNA.
• the siRNA is less than 30 nucleotides in length.
• the biologically active polynucleotide molecules comprise polynucleotide molecules complexed with chitosan.
• the chitosan is PEGylated.
• LNP comprises DNA molecules complexed with chitosan.
• the biologically active polynucleotide molecules comprise genomic material. In some aspects, the biologically active polynucleotide molecules are comprised in intact cells. In some aspects, the intact cells comprise living cells. In some aspects, the intact cells comprise intact bacterial, eukaryotic or archaeal cells. In some aspects, the intact cells comprise intact bacterial cells. In some aspects, the intact cells comprise living bacterial cells. In some aspects, the first excipient comprises a sugar or sugar alcohol. In some aspects, the first excipient comprises lactose, trehalose, sucrose, mannitol or sorbitol. In some aspects, the first excipient comprises sucrose. In some aspects, the surface, onto which materials are deposited, is rotating.
• the solvent is removed at reduced pressure. In some aspects, the solvent is removed via lyophilization. In some aspects, the lyophilization is carried out at a lyophilization temperature from about -20 °C to about -100 °C. In some aspects, the lyophilization temperature is about -40 °C. In some aspects, the reduced pressure is less than 400 mTor; 350 mTorr; 300 mTorr or 250 mTorr. In some aspects, the reduced pressure is about 100 mTorr. In some aspects, the method is a GMP method.
• the present disclosure provides pharmaceutical compositions prepared according to the methods of the present disclosure.
• the present disclosure provides methods of treating a lung disease, lung injury, or lung infection comprising administering an effective amount of a composition of the present disclosure or a composition produced by the methods of the present disclosure to a subject.
• the lung disease is interstitial lung diseases, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), pulmonary fibrosis or primary ciliary dyskinesia (PCD).
• COPD chronic obstructive pulmonary disease
• CF cystic fibrosis
• PCD primary ciliary dyskinesia
• the lung infection is a bacterial lung infection.
• the composition comprises bacteriophage.
• the composition comprises LNPs.
• the composition comprises siRNA.
• the present disclosure provides methods of stimulating an immune response in a subject comprising administering an effective amount of a composition of the present disclosure or a composition produced by the methods of the present disclosure to a subject, wherein the biologically active polynucleotide molecules encode an antigen.
• the composition comprises LNPs and mRNA.
• the present disclosure provides methods of treating a disease in a subject comprising administering an effective amount of a composition of the present disclosure or a composition produced by the methods of the present disclosure to the subject.
• the disease is a genetic disease.
• the disease is a lung disease.
• the disease is an infection.
• the present disclosure provides methods of treating a disease in a subject comprising: (i) reconstituting a composition of the present disclosure or a composition produced by the methods of the present disclosure, in a pharmaceutically acceptable vehicle; and (ii) administering an effective amount of the reconstituted composition to the subject.
• FIG. 1 shows titer loss of T7 after thin film freeze-dried with different excipient matrices. Note: the two segments of Y-axis were not in the same scale.
• FIG. 2 shows geometric particle size distribution of different TFFD phage formulations.
• FIG. 3 shows titer loss of T7 after thin film freeze-dried with various excipient matrices in different solid contents. Note: the two segments of Y-axis were not in the same scale.
• FIG. 4 shows geometric particle size distribution of TFFD processed phage formulations with different solid contents.
• FIG. 5 shows titer loss of T7 after thin film freeze-dried at different temperatures.
• FIG. 6 shows geometric particle size distribution of TFFD phage formulations processed at different temperatures.
• FIG. 7 shows titer loss of T7 after thin film freeze-dried in formulations with different initial phage concentration.
• 5E10, 5E09, 5E08, 5E07, and 5E06 are alternative expressions of 5xl0 10 PFU/mL, 5xl0 9 PFU/mL, 5xl0 8 PFU/mL, 5xl0 7 PFU/mL, and 5xl0 6 PFU/mL, respectively.
• FIG. 8 shows geometric particle size distribution of TFFD phage formulations processed with different phage concentration.
• 5E10, 5E09, 5E08, 5E07, and 5E06 are alternative expressions of 5xl0 10 PFU/mL, 5xl0 9 PFU/mL, 5xl0 8 PFU/mL, 5xl0 7 PFU/mL, and 5xl0 6 PFU/mL, respectively
• FIG. 9 shows titer loss of T7 after thin film freeze-dried in different buffer systems.
• FIG. 10 shows geometric particle size distribution of TFFD phage formulations processed with no buffer, PBS buffer, or SM buffer.
• FIG. 11 shows titer loss of T7 phage in each step of thin film freeze-drying.
• FIG. 12 shows X-ray diffraction patterns of TFFD phage powders.
• FIG. 13 shows powder morphology images by scanning electron microscopy.
• FIG. 14 shows phage morphology images by transmission election microscopy.
• FIG. 15 shows thermogravimetric analysis curves of TFFD phage powders.
• FIG. 16 shows water content in TFFD phage powder determined by TGA.
• FIG. 17 shows intracellular uptake of LNP formulations at different N/P ratios in HEK-293 cells measured by percent GFP expression (left axis) and fluorescence intensity (right axis).
• FIGS. 18A-18D shows characterization of LNP formulations.
• FIG. 18A size
• FIG. 18B zeta-potential
• FIG. 18C encapsulation efficiency
• FIGS. 19A-19C show stability of LNP formulations before and after nebulization in terms of (a) size, (b) zeta-potential, and (c) encapsulation efficiency.
• FIGS. 20A & 20B show efficiency of intracellular uptake in HEK-293 cells over 16 days after LNPs preparation.
• FIG. 20 A percent GFP expression
• FIG. 20B fluorescence intensity.
• FIGS. 21A-21D show in vitro intracellular uptake in terms of percent GFP expression (FIGS. 21A & 21C) and fluorescence intensity (FIGS. 21B & 21D) of LNP formulations before and after nebulization in HEK-293 and NuLi-1 cells.
• FIGS. 22A & 22B show efficacy and biodistribution of F2, F8, Fll, F17 formulations with luciferase mRNA.
• FIG. 22A Efficacy of the four lead formulations before and after nebulization in lung as measured in total flux of luminescence 6 h after intratracheal delivery of 15 pg of total mRNA.
• FIG. 22B Representative images of the luciferase expression in lungs, heart, liver, and kidneys measured by IVIS imaging.
• FIGS. 23A-23D show correlation between particle size and PEG-lipid.
• FIG. 23A Effect of PEG-lipid molar ratio on particle size before nebulization.
• FIG. 23B Effect of type of PEG-lipid on particle size before nebulization.
• FIG. 23C Effect of PEG-lipid molar ratio on particle size after nebulization.
• FIG. 23D Effect of type of PEG-lipid on particle size after nebulization.
• FIGS. 24A-24D show correlation between zeta potential and PEG-lipid.
• FIG. 24A Significant effects of PEG-lipid molar ratio on zeta potential before nebulization.
• FIG. 24B Significant effects of type of PEG-lipid on zeta potential before nebulization.
• FIG. 24C Significant effects of PEG-lipid molar ratio on zeta potential after nebulization.
• FIG. 24D Significant effects of type of PEG-lipid on zeta potential after nebulization.
• FIGS. 25A-25D show correlation of encapsulation efficiency and cholesterol molar ratio & type of phospholipid.
• FIG. 25A Significant correlation (p ⁇ 0.05) between encapsulation efficiency and cholesterol molar ratio before nebulization.
• FIG. 25B No significant effects (p > 0.05) of type of phospholipid on encapsulation efficiency before nebulization.
• FIG. 25C No significant correlation between encapsulation efficiency and cholesterol molar ratio after nebulization.
• FIG. 25D Significant effects of type of phospholipid on encapsulation efficiency after nebulization. **p ⁇ 0.01.
• FIGS. 26A-26F show correlation analysis between intracellular uptake (percent GFP expression and fluorescence intensity) and PEG-lipid molar ratio or type of phospholipid.
• FIG. 26A Significant effect of PEG-lipid molar ratio on percent GFP expression before nebulization.
• FIG. 26B Significant effect of type of phospholipid on percent GFP expression before nebulization.
• FIG. 26C Significant effect of PEG-lipid molar ratio on percent GFP expression before nebulization.
• FIG. 26D Significant effect of PEG-lipid molar ratio on percent GFP expression after nebulization.
• FIG. 26E No significant effect of type of phospholipid on percent GFP expression after nebulization.
• FIG. 26F Significant effect of PEG-lipid molar ratio on fluorescence intensity after nebulization.
• FIGS. 27A-27H show orthogonal trends of intracellular uptake in terms of percent GFP expression and fluorescence intensity, whereby dotted line represented nonsignificance and solid line represented significance.
• FIGS. 27A-27D Correlation between intracellular uptake and formulation properties before nebulization.
• FIGS. 27E-27H Correlation between intracellular uptake and formulation properties after nebulization.
• FIGS. 28A-28C show characterization of FNP formulations.
• FIG. 28A size
• FIG. 28B zeta-potential
• FIGS. 29A-29D show in vitro intracellular uptake in terms of percent GFP expression (FIGS. 29A & 29B) and fluorescence intensity (FIGS. 29C & 29D) of LNP formulations in HEK-293 and NuLi-1 cells.
• FIGS. 30A-30F show macroscopic appearance of 42 dry powder formulations.
• FIG. 30A formulations containing mannitol
• FIGG. 30B formulations containing mannitol and leucine
• FIG. 30C formulations containing sucrose
• FIG. 30D formulations containing sucrose and leucine
• FIG. 30E formulations containing trehalose
• FIG. 30F formulations containing trehalose and leucine.
• FIGS. 31A-31F show size, PDI and zeta potential of reconstituted dry powder formulations.
• FIG. 31 A size and PDI of reconstituted TFF formulations containing mannitol with/without leucine
• FIG. 3 IB size and PDI of reconstituted formulations containing sucrose with/without leucine
• FIG. 31C size and PDI of reconstituted TFF formulations containing trehalose with/without leucine
• FIG. 3 ID zeta potential of reconstituted TFF formulations containing mannitol with/without leucine
• FIG. 3 IE zeta potential of reconstituted TFF formulations containing sucrose with/without leucine
• FIG. 3 IE zeta potential of reconstituted TFF formulations containing trehalose with/without leucine.
• FIGS. 32 shows transfection efficiency of reconstituted formulations.
• FIGS. 33 shows structure of nanocomplexes.
• FIGS.34 shows scanning electron microscopy images of six refined dry powder formulations.
• FIGS. 35A-35C shows X-ray diffraction patterns of six refined dry powder formulations and raw mannitol, sucrose, and trehalose.
• FIG. 36 shows aerodynamic particle size distribution profile of refined TFF formulations.
• FIG. 37 shows Z-average size of LNP.
• FIG. 38 shows transfection efficiency of LNP-mRNA dry powder formulations in HEK-293 cells.
• FIGS. 39A & 39B show representative SEM micrographs of dry powders of SLNs.
• FIG. 39A spray dried SLNs;
• FIG. 39B SFNs prepared by TFFD. Top images were obtained with 3K magnification (scale bar: 10 pm) and bottom images with 10.5K magnification (scale bar: 2 pm).
• FIGS. 41A & 41B show a representative SEM image of thin-film freeze-dried siRNA-SFNs (FIG. 41A).
• FIG. 42 shows down-regulation of TNF-a release from J774A.1 cells by TNF- a-siRNA-SFNs, before (i.e. suspension) and after they were subjected to TFFD (i.e. Powder).
• TNF-a-siRNA complexed with Fipofectamine was used a control.
• Data rare mean ⁇ SD (n 4).
• Groups labeled with a, b, and d are different from groups labeled in c (p ⁇ 0.05).
• FIG. 44 shows evaluation of the function of the TFN-a siRNA in downregulating TNF-a release.
• FIG. 45 shows Next Gen impaction data for TopFluor-cholesterol labeled solid lipid nanoparticles dry powder. The fraction of nanoparticles recovered from each stage in the NGI is plotted. MOC is the micro-orifice collector and IP is the induction port. Error bars are the standard deviation for two trials.
• FIGS. 46A & 46B show physical characterization of the acid-sensitive-TNF-a siRNA-SFNs.
• FIG. 46A TEM image of the SEN.
• FIG. 46B in vitro release of the fluorescently labeled siRNA from acid-sensitive-TNF-a siRNA-SFNs.
• FIG. 47 shows physical appearance of the SEN dry powder.
• FIG. 48 shows SEM images of spray dried (left) and freeze dried (right) SEN powder.
• FIG. 49 show NGI deposition profile for spray-dried SLNs and freeze-dried SLNs. NGI data was collected over three independent trials and had recovery over 90%.
• FIG. 50 shows comparison of SLNs size distribution before and after drying using freeze drying (left) and spray drying (right).
• FIG. 51 shows a comparison of the morphology of shelf freeze-dried bacterial powder and thin- film freeze-dried bacterial powders.
• Left shelf freeze-dried bacteria powder, with sucrose (10% w/v) as cryoprotectant;
• Right TFFD bacteria powder with mannitol (250 ⁇ L of 5% w/w) as cryoprotectant.
• FIGS. 53A-53C show representative SEM images of thin-film freeze-dried pCMV- b powder (formulation P3).
• FIG. 54 shows the gel electrophoresis analysis of the plasmid before and after TFF formulation.
• Lane 1 pCMV-beta, Formulation 7
• Lane 2 pCMV-beta, Formulation 7, Hind III & EcoRl
• Lane 3 pCMV-beta, Formulation 7, EcoR I
• Lane 4 GeneRuler 1 kb Plus DNA Ladder (ThermoFisher)
• Lane 5 pCMV-beta, Formulation 7 after TFFD
• Lane 6 pCMV- beta, Formulation 7 after TFFD, Hind III & EcoR I
• Lane 7 pCMV-beta, Formulation 7 after TFFD, EcoR I
• Lane 8 pCMV-beta, Hind III & EcoR I
• Lane 9 pCMV-beta, EcoR I.
• pCMV-beta lanes 1 and 5, loaded 500 ng of plasmid, Others, -420 ng.
• FIG. 55 shows a representative TEM image of mRNA-LNPs after they were subjected to thin-film freeze-drying (formulation 5) and reconstitution.
• dry powder formulations of biologically active polynucleotides that can be made by a URF process. It was shown that, by the use of URF, the compositions can be stabilized such that the polynucleotides are protected from excessive degradation and components retain substantial biological activity after formulation.
• formulations include at least first excipient, such as sugar, to provide yet further stabilization.
• dry powders of the embodiments can comprise a wide variety of polynucleotide-containing compositions.
• the powders of the embodiments can be used to directly administer therapeutic agents, e.g., to the lungs.
• the aspects of the present invention provide new pharmaceutical formulations, formulation methods and administration modalities that demonstrate significant advantages over previously compositions and methods that have been used.
• a powder of the embodiment comprises viruses, such a bacteriophage. It has been shown that viruses processed into powders as detailed herein are able to retain substantial virus titer. Thus, methods and compositions provided herein can be used to stabilize virus, such as for storage and/or transportation. Likewise, virus -containing powders can be directly administered to patients in need thereof (or reconstituted prior to administration). For example, the virus may be an attenuated virus or vims like particles and the composition used as a vaccine to stimulate and immune response. In further aspects, the virus can be a bacteriophage and be used to treat a bacterial infection, such a lung infection. In still further aspects a vims can be gene therapy vector, for use in disease treatment.
• powders of the embodiments can comprise single stranded or double stranded RNA or DNA.
• Such polynucleotides can be encapsulated in or in complex with nanoparticles, such a lipid nanoparticle.
• polynucleotides, such as mRNAs or siRNAs are provided in complex with LNPs.
• a mRNA-LNP complex can encode a therapeutically active protein (e.g., for gene replacement therapy) or an antigen (e.g., for vaccination).
• the LNP provided in dry powders of the embodiments are formed from multiple lipid types, such as cationic lipids, phospholipids and/or PEGylated lipids.
• a RNA-LNP powder further comprises at least a first excipient, such as sugar or amino acid.
• dry powders can be directly administered (e.g., by dispersion in the lungs) to subjects to treat a disease or stimulate an immune response.
• powders are provided with LNPs comprising siRNA. It has been demonstrated that such compositions provide a stabilized formulation that is also ideal for delivery, e.g., such as by dispersion of the powder to the lungs.
• siRNAs could be employed to treat a wide range of disease. For example, in the case of an over-active or aberrant immune response, siRNA could target a gene that stimulates inflammatory immune response, such a TNF-alpha. In further aspects, siRNA could be targeted to oncogenes or genes of pathogens for disease treatment.
• polynucleotides such as DNA, as provided in powders in complex with chitosan nanoparticles.
• the chitosan nanoparticles are further modified by PEGylation.
• DNA molecules can be, e.g., plasmids or DNA expression vectors.
• DNA can encode a CRISPR system, to provide targeted gene replacement ins a subject.
• CRISPR system a CRISPR system
• DNA-complex containing powders can be directly administered (e.g., by dispersion in the lungs) to subjects to treat a disease.
• dry powder compositions of the embodiments comprise intact cells.
• the powders can comprise eukaryotic or bacterial cells.
• living cells can be formulated into URF powders and that such powders retain a high level of cell viability.
• dry powders can be used to stabilize, store and/or transport intact or living cells, such as bacterial cells.
• Such compositions have a wide range of potential uses.
• attenuated or inactivated bacteria could be formulated and used to stimulate immune responses.
• beneficial bacterial could be formulated to provide probiotic compositions.
• cell-containing dry powders can serve as means for directly delivering cells to patients as oral and/or aerosol formulations.
• bacteria-containing dry powder may have applications in agriculture, such as a stabilized biocontrol agent.
• bacteria-containing powders can be aerosolized and applied to a field, e.g., of crops.
• the present disclosure provides pharmaceutical compositions which may be prepared using a URF process, such as thin-film freezing process.
• a URF process such as thin-film freezing process.
• the methods employ an ultra-rapid freezing rate of up to 10,000 K/sec, e.g., at least 1,000, 2,000, 5,000 or 8,000 K/sec.
• these methods involve dissolving the components of the pharmaceutical composition into a solvent to form a precursor solution.
• the solvents may be either water or an organic solvent.
• the precursor solution is an aqueous solution that includes at least a first excipient and biologically active polynucleotide molecules.
• the precursor solution may contain less than 10% w/v of the therapeutic agent and excipient.
• the precursor solution may contain less than 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% w/v, or any range derivable therein.
• This precursor solution may be deposited on a surface which is at a temperature that causes the precursor solution to freeze. In some embodiments, this temperature may be below the freezing point of the solution at ambient pressure. In other embodiments, a reduced pressure may be applied to the surface causing the solution to freeze at a temperature below the ambient pressure’s freezing point.
• the surface may also be rotating or moving on a moving conveyer-type system thus allowing the precursor solution to distribute evenly on the surface. Alternatively, the precursor solution may be applied to surface in such a manner to generate an even surface.
• the solvent may be removed to obtain a pharmaceutical composition. Any appropriate method of removing the solvent may be applied including evaporation under reduced pressure or elevated temperature or lyophilization.
• the lyophilization may comprise a reduced pressure and/or a reduced temperature.
• a reduced temperature may be from 25 °C to about -200 °C, from 20 °C to about -175 °C, from about 20 °C to about -150 °C, from 0 °C to about -125 °C, from -20 °C to about -100 °C, from -75 °C to about -175 °C, or from -100 °C to about -160 °C.
• the temperature is from about -20 °C, -30 °C, -35 °C, -40 °C, -45 °C, -50 °C, -55 °C, -60 °C, -70 °C, -80 °C, -90 °C, -100 °C, -110 °C, -120 °C, -130 °C, -140 °C, -150 °C, -160 °C, -170 °C, -180 °C, -190 °C, to about -200 °C, or any range derivable therein.
• the solvent may be removed at a reduced pressure of less than 500 mTorr, 450 mTorr, 400 mTorr, 375 mTorr, 350 mTorr, 325 mTorr, 300 mTorr, 275 mTorr, 250 mTorr, 225 mTorr, 200 mTorr, 175 mTorr, 150 mTorr, 125 mTorr, 100 mTorr, 75 mTorr, 50 mTorr, or 25 mTorr.
• composition prepared using these methods may exhibit a brittle nature such that the composition is easily sheared into smaller particles when processed through a device.
• These compositions have high surface areas as well as exhibit improved flowability of the composition.
• Such flowability may be measured, for example, by the Carr index or other similar measurements.
• the Carr’s index may be measured by comparing the bulk density of the powder with the tapped density of the powder.
• Such compounds may exhibit a favorable Carr index and may result in the particles being better sheared to give smaller particles when the composition is processed through a secondary device to further process a powder composition.
• composition including biologically active polynucleotides
• Methods and composition of the embodiments concern biologically active polynucleotides.
• these can comprise single stranded or double stranded RNA or DNA.
• Such polynucleotides can be encapsulated in or in complex with nanoparticles.
• polynucleotides, such as mRNAs or siRNAs are provided in complex with LNPs.
• biologically active polynucleotides are provided in viruses, such as bacteriophage, or vims like particles.
• biologically active polynucleotides are provided in intact cells, such as living bacterial cells.
• a nucleic acid molecule of the embodiments encodes a therapeutic polypeptide.
• the therapeutic protein may be a protein, such as an enzyme that is non-functional or disrupted in a particular disease state (e.g., CFTR in cystic fibrosis).
• a polynucleotide of the embodiments encodes an antigen, such as an antigen from a pathogen or a cancer cell-associated antigen.
• the cancer associated antigen can be CD 19, CD20, ROR1, CD22, carcinoembryonic antigen, alphafetoprotein, CA-125, 5T4, MUC-1, epithelial tumor antigen, prostate-specific antigen, melanoma-associated antigen, mutated p53, mutated ras, HER2/Neu, folate binding protein, GD2, CD123, CD33, CD138, CD23, CD30 , CD56, c-Met, mesothelin, GD3, HERV-K, IL- HRalpha, kappa chain, lambda chain, CSPG4, ERBB2, EGFRvIII or VEGFR2.
• the antigen is GP240, 5T4, HER1, CD-33, CD-38, VEGFR-1, VEGFR-2, CEA, FGFR3, IGFBP2, IGF-1R, BAFF-R, TACI, APRIL, Fnl4, ERBB2 or ERBB3
• Antigens useful in the present disclosure may include those derived from viruses including, but not limited to, those from the family Arenaviridae (e.g., Lymphocytic choriomeningitis vims), Arterivims (e.g., Equine arteritis vims), Astroviridae (Human astrovirus 1), Birnaviridae (e.g., Infectious pancreatic necrosis virus, Infectious bursal disease virus), Bunyaviridae (e.g., California encephalitis virus Group), Caliciviridae (e.g., Caliciviruses), Coronaviridae (e.g., Human coronaviruses 299E and OC43), Deltavirus (e.g., Hepatitis delta virus), Filoviridae (e.g., Marburg virus, Ebola virus), Flaviviridae (e.g., Yellow fever vims group, Hepatitis C virus), Hepadnavirid
• Antigens useful in the present disclosure may include those derived from bacteria including, but not limited to, Streptococcus agalactiae, Fegionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhosae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Fyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Mycobacterium tuberculosis, Plasmodium falcipamm, Plasmodium vivax, Toxoplasma gondii, Trypanosoma rangeli, Trypanosoma cruzi, Trypanosoma rhodesiensei, Trypanosoma brucei, Schistosoma mansoni, Schistosoma
• Antigens useful in the present disclosure may include those derived from parasites including, but not limited to, Ancylostomahuman hookworms, Leishmania — all strains, Microsporidium, Necator human hookworms, Onchocerca filarial worms, Plasmodium — all human strains and simian species, Toxoplasma — all strains, Trypanosoma — all serotypes, and/or Wuchereria bancrofti filarial worms.
• parasites including, but not limited to, Ancylostomahuman hookworms, Leishmania — all strains, Microsporidium, Necator human hookworms, Onchocerca filarial worms, Plasmodium — all human strains and simian species, Toxoplasma — all strains, Trypanosoma — all serotypes, and/or Wuchereria bancrofti filarial worms.
• a nucleic acid for delivery in accordance with the embodiments is a DNA molecule.
• the DNA molecule may be an expression vector.
• expression vector refers to any type of genetic construct comprising a nucleic acid coding for a RNA capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of “control sequences,” which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host cell.
• vectors and expression vectors may contain nucleic acid sequences that serve other functions.
• a DNA expression vector may encode a therapeutic polypeptide or an antigen polypeptide.
• a DNA expression vector an encode the elements of CRISPR system. CRISPR systems
• CRISPR Clustered regularly interspaced short palindromic repeats
• Cas CRISPR-associated proteins
• CRISPR system refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas") genes, including sequences encoding a Cas gene, a tracr (transactivating CRISPR) sequence (e.g.
• tracrRNA or an active partial tracrRNA a tracr-mate sequence (encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer” in the context of an endogenous CRISPR system), and/or other sequences and transcripts from a CRISPR locus.
• the CRISPR/Cas nuclease or CRISPR/Cas nuclease system can include a noncoding RNA molecule (guide) RNA, which sequence-specifically binds to DNA, and a Cas protein (e.g., Cas9), with nuclease functionality (e.g., two nuclease domains).
• a CRISPR system can derive from a type I, type II, or type III CRISPR system, e.g., derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes.
• a Cas nuclease and gRNA are introduced into the cell.
• target sites at the 5' end of the gRNA target the Cas nuclease to the target site, e.g., the gene, using complementary base pairing.
• the target site may be selected based on its location immediately 5' of a protospacer adjacent motif (PAM) sequence, such as typically NGG, or NAG.
• PAM protospacer adjacent motif
• the gRNA is targeted to the desired sequence by modifying the first 20, 19, 18, 17, 16, 15, 14, 14, 12, 11, or 10 nucleotides of the guide RNA to correspond to the target DNA sequence.
• a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence.
• target sequence generally refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between the target sequence and a guide sequence promotes the formation of a CRISPR complex. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote formation of a CRISPR complex.
• the CRISPR system can induce double stranded breaks (DSBs) at the target site, followed by disruptions as discussed herein.
• Cas9 variants deemed “nickases,” are used to nick a single strand at the target site.
• Paired nickases can be used, e.g., to improve specificity, each directed by a pair of different gRNAs targeting sequences such that upon introduction of the nicks simultaneously, a 5' overhang is introduced.
• catalytically inactive Cas9 is fused to a heterologous effector domain such as a transcriptional repressor or activator, to affect gene expression.
• the target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides.
• the target sequence may be located in the nucleus or cytoplasm of the cell, such as within an organelle of the cell.
• a sequence or template that may be used for recombination into the targeted locus comprising the target sequences is referred to as an "editing template” or "editing polynucleotide” or “editing sequence”.
• an exogenous template polynucleotide may be referred to as an editing template.
• the recombination is homologous recombination.
• the CRISPR complex (comprising the guide sequence hybridized to the target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence.
• the tracr sequence which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g.
• tracr sequence has sufficient complementarity to a tracr mate sequence to hybridize and participate in formation of the CRISPR complex, such as at least 50%, 60%, 70%, 80%, 90%, 95% or 99% of sequence complementarity along the length of the tracr mate sequence when optimally aligned.
• One or more vectors driving expression of one or more elements of the CRISPR system can be introduced into the cell such that expression of the elements of the CRISPR system direct formation of the CRISPR complex at one or more target sites.
• Components can also be delivered to cells as proteins and/or RNA.
• a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors.
• two or more of the elements expressed from the same or different regulatory elements may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector.
• the vector may comprise one or more insertion sites, such as a restriction endonuclease recognition sequence (also referred to as a "cloning site").
• a restriction endonuclease recognition sequence also referred to as a "cloning site”
• one or more insertion sites are located upstream and/or downstream of one or more sequence elements of one or more vectors.
• a vector may comprise a regulatory element operably linked to an enzyme-coding sequence encoding the CRISPR enzyme, such as a Cas protein.
• Cas proteins include Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4, homologs
• the CRISPR enzyme can be Cas9 ⁇ e.g., from S. pyogenes or S. pneumonia).
• the CRISPR enzyme can direct cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence.
• the vector can encode a CRISPR enzyme that is mutated with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence.
• an aspartate-to-alanine substitution D10A in the RuvC I catalytic domain of Cas9 from S.
• pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand).
• a Cas9 nickase may be used in combination with guide sequence(s), e.g., two guide sequences, which target respectively sense and antisense strands of the DNA target. This combination allows both strands to be nicked and used to induce NHEJ or HDR.
• an enzyme coding sequence encoding the CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells.
• the eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human primate.
• codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence.
• Various species exhibit particular bias for certain codons of a particular amino acid.
• Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules.
• mRNA messenger RNA
• tRNA transfer RNA
• the predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization.
• a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of the CRISPR complex to the target sequence.
• the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
• Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
• any suitable algorithm for aligning sequences include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g. the Burrows Wheeler Aligner), Clustal W, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and
• the CRISPR enzyme may be part of a fusion protein comprising one or more heterologous protein domains.
• a CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains.
• protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity.
• Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
• reporter genes include, but are not limited to, glutathione-5- transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP).
• GST glutathione-5- transferase
• HRP horseradish peroxidase
• CAT chloramphenicol acetyltransferase
• beta galactosidase beta-glucuronidase
• a CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4A DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US 20110059502, incorporated herein by reference.
• siNA small inhibitory nucleic acid
• siRNA and double- stranded RNA have been described in U.S. Pat. Nos. 6,506,559 and 6,573,099, as well as in U.S. Patent Applications 2003/0051263, 2003/0055020, 2004/0265839, 2002/0168707, 2003/0159161, and 2004/0064842, all of which are herein incorporated by reference in their entirety.
• a siNA may comprise a nucleotide and a nucleic acid or nucleotide analog.
• siNA form a double-stranded structure; the double-stranded structure may result from two separate nucleic acids that are partially or completely complementary.
• the siNA may comprise only a single nucleic acid (polynucleotide) or nucleic acid analog and form a double-stranded structure by complementing with itself (e.g., forming a hairpin loop).
• the double-stranded structure of the siNA may comprise 16, 20, 25, 30, 35, 40, 45, 50, 60, 65, 70, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500 or more contiguous nucleobases, including all ranges therein.
• the siNA may comprise 17 to 35 contiguous nucleobases, more preferably 18 to 30 contiguous nucleobases, more preferably 19 to 25 nucleobases, more preferably 20 to 23 contiguous nucleobases, or 20 to 22 contiguous nucleobases, or 21 contiguous nucleobases that hybridize with a complementary nucleic acid (which may be another part of the same nucleic acid or a separate complementary nucleic acid) to form a double-stranded structure.
• a complementary nucleic acid which may be another part of the same nucleic acid or a separate complementary nucleic acid
• RNA interference double- stranded RNA
• siRNA small interfering RNA
• RNAi there are several factors that need to be considered, such as the nature of the siRNA, the durability of the silencing effect, and the choice of delivery system.
• the siRNA that is introduced into the organism will typically contain exonic sequences.
• the RNAi process is homology dependent, so the sequences must be carefully selected so as to maximize gene specificity, while minimizing the possibility of cross-interference between homologous, but not gene-specific sequences.
• the siRNA exhibits greater than 80%, 85%, 90%, 95%, 98%, or even 100% identity between the sequence of the siRNA and the gene to be inhibited. Sequences less than about 80% identical to the target gene are substantially less effective. Thus, the greater homology between the siRNA and the gene to be inhibited, the less likely expression of unrelated genes will be affected.
• the size of the siRNA is an important consideration.
• the present invention relates to siRNA molecules that include at least about 19- 25 nucleotides and are able to modulate gene expression.
• the siRNA is preferably less than 500, 200, 100, 50, or 25 nucleotides in length. More preferably, the siRNA is from about 19 nucleotides to about 25 nucleotides in length.
• a target gene generally means a polynucleotide comprising a region that encodes a polypeptide, or a polynucleotide region that regulates replication, transcription, or translation or other processes important to expression of the polypeptide, or a polynucleotide comprising both a region that encodes a polypeptide and a region operably linked thereto that regulates expression.
• the targeted gene can be chromosomal (genomic) or extrachromosomal. It may be endogenous to the cell, or it may be a foreign gene (a transgene). The foreign gene can be integrated into the host genome or it may be present on an extrachromosomal genetic construct such as a plasmid or a cosmid.
• the targeted gene can also be derived from a pathogen, such as a virus, bacterium, fungus, or protozoan, which is capable of infecting an organism or cell.
• Target genes may be viral and pro-viral genes that do not elicit the interferon response, such as retroviral genes.
• the target gene may be a protein-coding gene or a non-protein coding gene, such as a gene that codes for ribosomal RNAs, spliceosomal RNA, tRNAs, etc.
• a target gene is one involved in or associated with the progression of cellular activities important to disease or of particular interest as a research object.
• developmental genes e.g.
• tumor suppressor genes e.g., APC, CYLD, HIN-1, KRAS2b, pl6, pl9, p21, p27, p27mt, p53, p57, p73, PTEN, Rb, Uteroglobin, Skp2, BRCA-1, BRCA-2, CHK2, CDKN2A, DCC, DPC4, MADR2/JV18, MEN1, MEN2, MTS1, NF1, NF2, VHL, WRN, WT1, CFTR, C-CAM, CTS- 1, zacl, ras, MMAC1, FCC, MCC, FUS1, Gene 26 (CACNA2D2), PL6, Beta* (BLU), Luc
• siRNA can be obtained from commercial sources, natural sources, or can be synthesized using any of a number of techniques well-known to those of ordinary skill in the art.
• one commercial source of predesigned siRNA is Ambion®, Austin, Tex.
• An inhibitory nucleic acid that can be applied in the compositions and methods of the present invention may be any nucleic acid sequence that has been found by any source to be a validated downregulator of a protein of interest.
• an isolated siRNA molecule of at least 19 nucleotides having at least one strand that is substantially complementary to at least ten but no more than thirty consecutive nucleotides of a nucleic acid that encodes a TNF-a, and that reduces the expression of the TNF-a protein.
• the siRNA may also comprise an alteration of one or more nucleotides. Such alterations can include the addition of non-nucleotide material, such as to the end(s) of the 19 to 25 nucleotide RNA or internally (at one or more nucleotides of the RNA). In certain aspects, the RNA molecule contains a 3'-hydroxyl group. Nucleotides in the RNA molecules of the present invention can also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleo tides.
• the double- stranded oligonucleotide may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or other modified backbones known in the art, or may contain non-natural internucleoside linkages. Additional modifications of siRNAs (e.g. , 2'-0-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, “universal base” nucleotides, 5-C-methyl nucleotides, one or more phosphorothioate internucleotide linkages, and inverted deoxyabasic residue incorporation) can be found in U.S. Application Publication 2004/0019001 and U.S. Pat. No. 6,673,611 (each of which is incorporated by reference in its entirety). Collectively, all such altered nucleic acids or RNAs described above are referred to as modified siRNAs.
• mRNA messenger RNA
• a polynucleotide of the embodiments is a mRNA molecule.
• the mRNA may encode a therapeutic polypeptide or an antigen.
• mRNA molecules comprise a 5’ cap; a 5’ UTR; a 3’UTR; and/or a poly-A tail.
• mRNA molecules can provide a more direct method of expressing a polypeptide of interest in a target cell. However, such molecules are typically highly liable and rapidly degraded.
• LNP and/or URF processing according to the embodiments can be used to substantially stabilize mRNA.
• mRNA is provided encapsulated in or in complex with LNPs.
• compositions of the embodiments comprise intact and/or living cells.
• the cells can be eukaryotic, archaeal cells and/or bacterial cells.
• the cells can comprise human cells (e.g., human iPS cells), fungal cells (e.g., yeast cell), or plant cells.
• the cells comprise bacterial cells.
• the bacterian may be gram positive or gram negative bacteria.
• the cells may comprise bacteria that are protective to crop plants or express proteins that help control insect damage.
• the bacteria can be bacteria that are beneficial to human subject, such healthy gut bacteria.
• the cells are engineered cells, such as engineered bacteria.
• a bacterial composition of the embodiments can be a probiotic composition.
• a probiotic composition may comprise one or more bacteria from Bacteroidetes, Firmicutes, Proteobacteria, Verrucomicrobiae, and Actinobacteria.
• a bacterial cell can be an attenuated or inactivated bacterial cell (e.g., for use in a vaccine).
• the attenuated or inactivated bacteria can be Streptococcus agalactiae, Legionella pneumophilia, Streptococcus pyogenes, Escherichia cob, Neisseria gonorrhosae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus, Mycobacterium tuberculosis, Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trypanosoma rangeli, Trypanosoma cruzi, Trypanosoma rhodesiense
• compositions of the embodiments comprise viruses, viral vector and/or VLPs.
• the virus can be a vims that infects mammalian cells or bacterial cells (a bacteriophage).
• the vims comprises a bacteriophage that infects bacteria that are pathogenic to human subjects.
• the bacteriophage infects bacteria that cause lung infections.
• a virus can be an attenuated or inactivated vims (e.g., for use in a vaccine).
• the attenuated or inactivated vims can be from the family Arenaviridae (e.g., Lymphocytic choriomeningitis virus), Arterivims (e.g., Equine arteritis virus), Astroviridae (Human astrovirus 1), Birnaviridae (e.g., Infectious pancreatic necrosis virus, Infectious bursal disease virus), Bunyaviridae (e.g., California encephalitis vims Group), Caliciviridae (e.g., Caliciviruses), Coronaviridae (e.g., Human coronaviruses 299E and OC43), Deltavims (e.g., Hepatitis delta virus), Filoviridae (e.g., Marburg vims, Ebola vim
• Arenaviridae e
• the virus can be viral vector, such as an engineered viral vector.
• viral vectors in include, but are not limited to adenoviral vectors, retroviral vectors and adeno-associated viral vectors.
• nanoparticle refers to any material having dimensions in the 1-1,000 nm range. In some embodiments, nanoparticles have dimensions in the 50-500 nm range. Nanoparticles used in the present embodiments include such nanoscale materials as a lipid-based nanoparticle, a superparamagnetic nanoparticle, a nanoshell, a semiconductor nanocrystal, a quantum dot, a polymer-based nanoparticle, a silicon-based nanoparticle, a silica-based nanoparticle, a metal-based nanoparticle, a fullerene and a nanotube (Ferrari, 2005).
• conjugation of polypeptide or nucleic acids to nanoparticles provides structures with potential application for targeted delivery, controlled release, enhanced cellular uptake and intracellular trafficking, and molecular imaging of therapeutic peptides in vitro and in vivo (West, 2004; Stayton et al, 2000; Ballou et al, 2004; Frangioni, 2003; Dubertret et al, 2002; Michalet et al, 2005; Dwarakanath et al, 2004.
• nanoparticles for use in accordance with the embodiments include chitosan as a component.
• chitosans are a family of cationic, binary hetero-polysaccharides composed of (l®4)-linked 2-acetamido-2-deoxy-P-D-glucose (GlcNAc, A-unit) and 2-ami no-2-deoxy-P-D-glucose, (GlcN; D-unit) (Varum et al, 1991).
• the chitosan has a positive charge, stemming from the de-acetylated amino group ( — NH 3 + ).
• Chitosan, chitosan derivatives, or salts (e.g., nitrate, phosphate, sulphate, hydrochloride, glutamate, lactate or acetate salts) of chitosan may be used and are included within the meaning of the term “chitosan.”
• chitosan derivatives is intended to include ester, ether, or other derivatives formed by bonding of acyl and/or alkyl groups with — OH groups, but not the N3 ⁇ 4 groups, of chitosan. Examples are O-alkyl ethers of chitosan and O- acyl esters of chitosan.
• Modified chitosans are also considered “chitosan derivatives.” Many chitosans and their salts and derivatives are commercially available (e.g., SigmaAldrich, Milwaukee, WI). In preferred aspects, chitosan nanoparticles of the embodiments are PEGylated. [00129] Methods of preparing chitosans and their derivatives and salts are also known, such as boiling chitin in concentrated alkali (50% w/v) for several hours. This produces chitosan wherein 70%-75% of the N-acetyl groups have been removed.
• Chitosans may be obtained from any source known to those of ordinary skill in the art.
• chitosans may be obtained from commercial sources.
• Chitosans may be obtained from chitin, the second most abundant biopolymer in nature.
• Chitosan is prepared by N-deacetylation of chitin.
• Chitosan is commercially available in a wide variety of molecular weight (e.g., 10-1000 kDa) and usually has a degree of deacetylation ranging between 70% -90%.
• the chitosan (or chitosan derivative or salt) used preferably has a molecular weight of 4,000 Dalton or more, preferably in the range 25,000 to 2,000,000 Dalton, and most preferably about 50,000 to 300,000 Dalton.
• Chitosans of different molecular weights can be prepared by enzymatic degradation of high molecular weight chitosan using chitosanase or by the addition of nitrous acid. Both procedures are well known to those skilled in the art and are described in various publications (Li etai, 1995; Allan and Peyron, 1995; Domard and Cartier, 1989).
• the chitosan is water-soluble and may be produced from chitin by deacetylation to a degree of greater than 40%, preferably between 50% and 98%, and more preferably between 70% and 90%.
• Some methods of producing chitosan involve recovery from microbial biomass, such as the methods taught by U.S. Pat. No. 4,806,474 and U.S. Patent Application No. 2005/0042735, herein incorporated by reference.
• Another method, taught by U.S. Pat. No. 4,282,351 teaches only how to create a chitosan-beta-glucan complex.
• the chitosan, chitosan derivative, or salt used in the present invention is water soluble.
• Chitosan glutamate is water soluble.
• water soluble it is meant that that the chitosan, chitosan derivative, or salt dissolves in water at an amount of at least 10 mg/ml at room temperature and atmospheric pressure.
• the chitosan, chitosan derivative, or salt used in the present invention has a positive charge.
• Chitosan nanoparticles of the embodiments are provided in complex with a nucleic acid, such as DNA.
• Lipid-based nanoparticles include liposomes, lipid preparations and lipid-based vesicles (e.g., DOTAP:cholesterol vesicles). Lipid-based nanoparticles may be positively charged, negatively charged or neutral. In certain embodiments, the lipid-based nanoparticle is neutrally charged (e.g., a DOPC liposome).
• a “liposome” is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes may be characterized as having vesicular structures with a bilayer membrane, generally comprising a phospholipid, and an inner medium that generally comprises an aqueous composition. Liposomes provided herein include unilamellar liposomes, multilamellar liposomes and multi vesicular liposomes. Liposomes provided herein may be positively charged, negatively charged or neutrally charged. In certain embodiments, the liposomes are neutral in charge.
• a multilamellar liposome has multiple lipid layers separated by aqueous medium. They form spontaneously when lipids comprising phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991). Lipophilic molecules or molecules with lipophilic regions may also dissolve in or associate with the lipid bilayer.
• a polypeptide or nucleic acids may be, for example, encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the polypeptide/nucleic acid, entrapped in a liposome, complexed with a liposome, or the like.
• Additional liposomes which may be useful with the present embodiments include cationic liposomes, for example, as described in W002/100435A1, U.S Patent 5,962,016, U.S. Application 2004/0208921, W003/015757A1, WO04029213A2, U.S. Patent 5,030,453, and U.S. Patent 6,680,068, all of which are hereby incorporated by reference in their entirety without disclaimer.
• a process of making liposomes is also described in W004/002453A1.
• Neutral lipids can be incorporated into cationic liposomes (e.g., Farhood et al., 1995).
• a liposome varies depending on the method of synthesis. Liposomes in the present embodiments can be a variety of sizes. In certain embodiments, the liposomes are small, e.g., less than about 100 nm, about 90 nm, about 80 nm, about 70 nm, about 60 nm, or less than about 50 nm in external diameter.
• a DOTAP:cholesterol liposome for use according to the present embodiments comprises a size of about 50 to 500 nm.
• Such liposome formulations may also be defined by particle charge (zeta potential) and/or optical density (OD).
• a DOTAP:cholesterol liposome formulation will typically comprise an OD400 of less than 0.45 prior to nucleic acid incorporation.
• the overall charge of such particles in solution can be defined by a zeta potential of about 50-80 mV.
• any protocol described herein, or as would be known to one of ordinary skill in the art may be used. Additional non-limiting examples of preparing liposomes are described in U.S. Patents 4,728,578, 4,728,575, 4,737,323, 4,533,254, 4,162,282, 4,310,505, and 4,921,706; International Applications PCT/US85/01161 and PCT/US 89/05040; U.K. Patent Application GB 2193095 A; Mayer et al, 1986; Hope et al, 1985; Mayhew et al. 1987; Mayhew et al, 1984; Cheng et al, 1987; and Liposome Technology, 1984, each incorporated herein by reference).
• the lipid based nanoparticle is a neutral liposome (e.g., a DOPC liposome).
• Neutral liposomes or “non-charged liposomes”, as used herein, are defined as liposomes having one or more lipid components that yield an essentially - neutral, net charge (substantially non-charged).
• essentially neutral or “essentially non- charged”, it is meant that few, if any, lipid components within a given population (e.g., a population of liposomes) include a charge that is not canceled by an opposite charge of another component (/. ⁇ ?
• neutral liposomes may include mostly lipids and/or phospholipids that are themselves neutral under physiological conditions (i.e., at about pH 7).
• Liposomes and/or lipid-based nanoparticles of the present embodiments may comprise a phospholipid.
• a single kind of phospholipid may be used in the creation of liposomes (e.g., a neutral phospholipid, such as DOPC, may be used to generate neutral liposomes).
• a neutral phospholipid such as DOPC
• more than one kind of phospholipid may be used to create liposomes.
• Phospholipids include, for example, phosphatidylcholines, phosphatidylglycerols, and phosphatidylethanolamines; because phosphatidylethanolamines and phosphatidyl cholines are non-charged under physiological conditions (i.e. , at about pH 7), these compounds may be particularly useful for generating neutral liposomes.
• the phospholipid DOPC is used to produce non-charged liposomes.
• a lipid that is not a phospholipid e.g., a cholesterol
• Phospholipids include glycerophospholipids and certain sphingolipids.
• Phospholipids include, but are not limited to, dioleoylphosphatidylycholine ("DOPC"), egg phosphatidylcholine (“EPC”), dilauryloylphosphatidylcholine (“DLPC”), dimyristoylphosphatidylcholine (“DMPC”), dipalmitoylphosphatidylcholine (“DPPC”), distearoylphosphatidylcholine (“DSPC”), l-myristoyl-2-palmitoyl phosphatidylcholine (“MPPC”), l-palmitoyl-2-myristoyl phosphatidylcholine (“PMPC”), l-palmitoyl-2-stearoyl phosphatidylcholine (“PSPC”), l-stearoyl-2-palmitoyl phosphatidylcholine (“SPPC”), dil
• Phospholipids may be from natural or synthetic sources. However, phospholipids from natural sources, such as egg or soybean phosphatidylcholine, brain phosphatidic acid, brain or plant phosphatidylinositol, heart cardiolipin and plant or bacterial phosphatidylethanolamine are not used, in certain embodiments, as the primary phosphatide (/. ⁇ ? ., constituting 50% or more of the total phosphatide composition) because this may result in instability and leakiness of the resulting liposomes.
• natural sources such as egg or soybean phosphatidylcholine, brain phosphatidic acid, brain or plant phosphatidylinositol, heart cardiolipin and plant or bacterial phosphatidylethanolamine are not used, in certain embodiments, as the primary phosphatide (/. ⁇ ? ., constituting 50% or more of the total phosphatide composition) because this may result in instability and leakiness of the resulting liposomes.
• the present disclosure comprises one or more excipients formulated into pharmaceutical compositions.
• the excipients used herein are water soluble excipients. These water soluble excipients include saccharides such as disaccharides.
• the excipient comprises sucrose, trehalose, or lactose, a trisaccharide such as fructose, sucrose, glucose, glacatose, or raffinose, polysaccharides such as starches or cellulose, or a sugar alcohol such as xylitol, sorbitol, or mannitol.
• these excipients are solid at room temperature.
• sugar alcohols include erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotritol, maltotetraitol, or a polyglycitol.
• the present pharmaceutical compositions may further exclude a hydrophobic or waxy excipient such as waxes and oils.
• hydrophobic excipients include hydrogenated oils and partially hydrogenated oils, palm oil, soybean oil, castor oil, camauba wax, beeswax, palm wax, white wax, castor wax, or lanoline. Additionally, the present disclosure may further comprise one or more amino acids or an amide or ester derivative thereof.
• the amino acids used may be one of the 20 canonical amino acids such as glycine, alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, tryptophan, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, proline, arginine, histidine, lysine, aspartic acid, or glutamic acid.
• These amino acids may be in the D or L orientation or the amino acids may be an a-, b-, g-, or S- amino acids.
• one of the common non-canonical amino acids may be used such as carnitine, GABA, carboxyglutamic acid, levothyroxine, hydroxyproline, seleonmethionine, beta alanine, ornithine, citrulline, dehydroalanine, d-aminolevulinic acid, or 2-aminoisobutyric acid.
• the amount of the excipient in the precursor solution for making a powder composition is from about 0.5% to about 20% w/w, from about 1% to about 10% w/w, from about 2% to about 8% w/w, or from about 2% to about 5% w/w.
• the amount of the excipient in the precursor solution comprises from about 0.5%, 0.75%, 1%, 1.25%, 1.5%, 1.75%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 6%, 7%, 8%, 9%, to about 10% w/w, or any range derivable therein.
• the amount of the excipient in a dry powder of the embodiments is about 10% to 99.5% w/w of the total weight of the pharmaceutical composition, such as about 50% to 99%, 75% to 99% or 80% to 98%.
• drug As used herein, the terms “drug”, “pharmaceutical”, “therapeutic agent”, and “therapeutically active agent” are used interchangeably to represent a compound which invokes a therapeutic or pharmacological effect in a human or animal and is used to treat a disease, disorder, or other condition. In some embodiments, these compounds have undergone and received regulatory approval for administration to a living creature.
• the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
• the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects or experimental studies. Unless another definition is applicable, the term “about” refers to ⁇ 10% of the indicated value.
• the term “substantially free of’ or “substantially free” in terms of a specified component is used herein to mean that none of the specified component has been purposefully formulated into a composition and/or is present only as a contaminant or in trace amounts. The total amount of all containments, by-products, and other material is present in that composition in an amount less than 2%.
• the term “more substantially free of’ or “more substantially free” is used to represent that the composition contains less than 1 % of the specific component.
• the term “essentially free of’ or “essentially free” contains less than 0.5% of the specific component.
• nanoparticle has its customary and ordinary definition and refers to discrete particles which behave as a whole unit rather than as individual molecules within the particle.
• a nanoparticle may have a size from about 1 to about 10,000 nm with ultrafine nanoparticles having a size from 1 nm to 100 nm, fine particles having a size from 100 nm to 2,500 nm, and coarse particles having a size from 2,500 nm to 10,000 nm.
• the nanoaggregates described herein may comprise a composition of multiple nanoparticles and have a size from about 10 nm to about 100 pm.
• Example 1 Inhalable Bacteriophage Solid Formulations Using Thin Film Freezing
• D-(+)-trehalose, dihydrate, sodium chloride, magnesium sulfate, sucrose, and Lysogeny broth (LB) media, LB agar, were purchased from Thermo Fisher Scientific (Waltham, MA, US); leucine and mannitol were purchased from Spectrum (New Brunswick, NJ, US); T7 bacteriophage and its host BL21 bacteria strain were purchased from Millipore Sigma (Burlington, MA, US); Phosphate saline buffer (PBS), Trizma® base, Tris- HC1 were purchased from Sigma-Aldrich (St. Louis, MO, US).
• PBS Phosphate saline buffer
• Trizma® base Tris- HC1
• T7 amplification and phage reconstitution were amplified according to manufacturer’s protocol. Briefly, phage were added to BL21 liquid cultures (OD600 of 0.2-0.3) at a multiplicity of infection (MOI) 0.001-0.01 and amplified for 1-3 hours at 37 °C, 250 RPM until lysis was observed. Bacterial lysate was collected, clarified with 5M NaCl/LB and spun down at 10,000 rpm in a Sorvall XFR Centrifuge (Thermo Fisher Scientific, Waltham, MA, US) for 30 minutes at 4 °C.
• MOI multiplicity of infection
• the supernatant containing the phage was collected and phage were further precipitated by incubating phage samples with a 50% PEG 8000 solution overnight at 4 °C. Once precipitated, phage were pelleted by spinning down at 14,000 rpm and resuspended in either PBS or SM buffer and collected in 1.5 mL microcentrifuge tubes. To further purify the phage, a second PEG precipitation step was performed with the resuspended phage, by precipitating with 50% PEG 8000 solution on ice for at least 30 minutes.
• This lysate-PEG mixture was then centrifuged at 14,000 rpm for 30 minutes and the resulting phage pellet was resuspended in 50-100 ⁇ L of either PBS or SM buffer. Amplified phage was quantified by standard double-layer plaque assay and stored at 4°C.
• Phage viability test The amount of viable phage in the solution and powder samples was determined by titering (i.e. an activity counting assay). The TFFD processed phage powders were reconstituted in sterile water to a final concentration of 10 mg/ml. In the viability test for freezing step, the frozen thin films were collected and thaw at room temperature before titering. The lytic bioactivity of phage was assayed by performing a standard double-layer plaque assay. Briefly, testing phage solution were prepared in 10-fold serial dilutions using LB media.
• [00163] Formulation preparation Several excipients that were commonly used in solid phage formulation research were selected, including three disaccharides (lactose, sucrose, and trehalose), one sugar alcohol (mannitol), and one amino acid (leucine). These excipients were incorporated in the formulations either alone or combined with another one to form binary excipient matrix. The combination was sugar and mannitol or sugar and leucine in a ratio of 90:10 to 50:50. The formulation solutions were prepared in a solid content range of 0.25% to 10% which corresponds to the solution concentrations of 2.5 mg/mL to 100 mg/mL. Solid content refers to the weight to volume concentration of all components in the pre-TFFD solution formulation.
• the initial titers of phage stocks were in multitude of 10 11 PFU/mL to IQ 12 PFlJ/ml. and they were added to the formulations at 100 to 1000 folds dilution to achieve a final titer of 5xl0 8 to 10 9 PFUl/mL, unless otherwise noted.
• the solutions were prepared in PBS (pH 7.4), SM buffer (pH 7.4-7.5), or water. SM buffer (without gelatin) was prepared according to the recipe provided by Cold Spring Harbor Protocol.
• phage powder by TFFD Aqueous phage solutions were passed through a standard 5 mL or 10 mL syringe. The droplets fell from a height of 10 cm above an absolute-flat bottom stainless-steel container which was pre-chilled by submerging it to liquid nitrogen. As a result of thermal conductivity through the steel, the resulting equilibrium surface temperatures of surface of the container’s bottom were below freezing point of the solutions and could go down to as low as colder than -100 °C. In this experiment, the working temperature was controlled by adjusting the height of the container in the liquid nitrogen. The temperature was controlled within -65 to -75 °C unless otherwise noted.
• the surface temperature of the container’s bottom was verified with a thermocouple that was installed on the bottom surface with a wire.
• a thermocouple that was installed on the bottom surface with a wire.
• droplets deformed into thin films and froze immediately.
• the frozen thin films were manually removed from the surface by a stainless-steel blade.
• the container with frozen thin films was then filled with liquid nitrogen.
• the films and liquid nitrogen were poured into a 20 mL lyophilization vial which was then covered with a double layer Kim-wipe to prevent particles from exiting the vial during vacuum drying.
• the vials were transferred directly to a -80°C freezer to evaporate excess liquid nitrogen and hold till being placed into lyophilizer.
• a Virtis Advantage Lyophilizer (The Virtis Company, Inc., Gardiner, NY) was used to dry the frozen slurries. Primary drying was carried out at -40°C for 2000 min at 100 mTorr and secondary drying at 25°C for 1250 min at 100 mTorr. A 12-h linear ramp of the shelf temperature from -40°C to +25°C was used at 100 mTorr between these two drying steps. After the cycle was done, the containers were capped tightly and then stored in a vacuum chamber immediately after being removed from the lyophilizer.
• X-ray diffraction (XRD) pattern The crystallinity of TFFD processed phage powder was detected using an X-ray diffractometer (MiniFlex 600, Rigaku Co., Japan) under ambient conditions. Powders were spread on the glass slides and were exposed to Cu Ka radiation at 15 mA and 40 kV. The scattered intensity was collected by a detector for a 20 ranging from 5 to 50° at a step size of 0.025°, and a speed of 27min, respectively.
• Thermogravimetric analysis was conducted using the Mettler Thermogravimetric Analyzer (Mettler Toledo, Columbus, OH, US). Samples in a size of 1-3 mg were loaded in 70 pi alumina pans and the pans were loosely capped with a lid that has a vent hole. Samples were heated up from 35 °C to 400 °C at a rate of 10 °C/min. The system was purged by nitrogen at a flow rate of 50 L/min. The percentage of change in mass over initial mass was calculated and plotted against temperature. The percent of weight loss at 120 °C was used to determine the water content in powders.
• Phage were imaged using a FEI Tecnai TEM (FEI Tecnai, OR, US) at 80 kV equipped with an AMT Advantage HR lkxlk digital camera (Advanced Microscopy Techniques, MA, US).
• sucrose containing formulations preserved the phage lytic activity better than lactose and trehalose.
• sugars alone could not sufficiently protect phage and has adverse effect on phage stability.
• Most of the mannitol containing formulations experienced full titer loss. It was obvious that mannitol was detriment to the phage.
• the negative impact of mannitol to phage was previously reported with lyophilized M13 phage research, in which it was observed that the titer loss increases with the increase of mannitol ratio in the mannitol-trehalose binary system.
• sucrose: leucine 80:20 with a titer loss of 1.47 (log, PFU), was found to be the best formulation to preserve phage viability.
• FIG. 4 shows the change of particle size distributions with the increase of solid contents in formulations.
• particle size and solid content has a negative correlation, i.e., lower solid content generates smaller particle size.
• exceptions were seen in the tested formulation groups, for example, in lactose group the greatest particle size was when solid content was 0.5% instead of 10%.
• the particle size was significantly impacted by the amount of phage in the formulations.
• the Dv50 of phage powders increased when the initial titer was reduced from 5E10 PFU/mL to 5E07 PFU/mL.
• the drastic change of particle sizes between 5E10 PFU/mL and 5E09 PFU/mL was likely due to the presence of residual salt molecules from the stock solution.
• the stock was diluted only 10 folds in 5E10 PFU/mL formulation, which can be sufficiently impactful to the crystallization behavior of the formulation during the process. It is encouraging to find out that the Dv50 was reduced to 2.61 ⁇ 0.07 pm and the percentile of 1-5 pm particles was improved to 67.2 ⁇ 2.42% (FIG. 8)
• TFFD involves two steps that could impair phage viabilities: freezing and drying.
• titers were examined after freezing and drying, respectively.
• FIG. 11 incorporating buffer system reduced titer loss in both freezing and drying steps regardless of excipient compositions. Phage survived the most in PBS buffer system during the freezing step. Most titer loss occurred in drying step in PBS and no buffer samples. In contrast, no titer loss was found in the drying step in SM buffer sample when the other excipients were trehalose: leucine 90:10.
• Buffer system are routinely included in solid products due to their ability to stabilize the pH during freezing process. However, this might not be the protection mechanism in this case since phage are generally insensitive to pH and pH shift can be limited in a rapid freezing process. Therefore, the protection might be a result of molecular-level interactions between phage capsid proteins and salt molecules.
• the protective effect of buffer system in drying step could be indirectly: the existence of salt molecules changed the crystal shapes in the frozen thin films, which ultimately lead to different drying behavior.
• phage Morphology of phage.
• the morphology of T7 phage has already been well characterized. Basically, the phage is composed by an icosahedral (twenty faces) protein capsid with a relatively short tail, on which long tail fibers attached (as shown in the carton in FIG. 14.
• TFFD is a desirable alternative to currently developed particle engineering methods given it eliminates stresses to phages from the vibration of nozzles in SD, SFD, and ASFD, and avoided the thermal stress in SD process. Therefore, development of bacteriophage inhalable dry powder using thin film freezing technology is a worthy strategy.
• DLin-MC3-DMA was purchased from Biofine International Inc., Vancouver, BC.
• 1,2- dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-rac- glycero-3- methoxypolyethylene glycol-2000 (DMG-PEG-2000), l,2-distearoyl-sn-glycero-3- phosphocholine (DSPC), l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [Amino (Polyethylene Glycol) 2000 (DSPE-PEG 2000), and (Delta 9 cis)/l,2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids, AL, USA.
• N- (methylpolyoxyethyleneoxycarbonyl)-l,2-dimyristoyl-sn-glycero-3-phosphoehtanolamine (DMPE-PEG 2000) was purchased from NOF Corporation, Tokyo, JP. Cholesterol was purchased from Sigma Aldrich, MO. Ethanol (molecular grade) was purchased from Decon Laboratories, Inc., PA. CleanCap® Enhanced Green Fluorescent Protein (EGFP) mRNA and CleanCap® Firefly luciferase (FLuc) mRNA were purchased from TriLink, San Diego, CA, USA.
• Lipid nanoparticles containing EGFP mRNA or FLuc mRNA were prepared by combining an aqueous phase (mRNA diluted in 100 mM sodium acetate citrate buffer, pH 3.0) and an organic phase containing ethanol and lipids according to each formulation (Table 2) using a microfluidic mixer (Precision Nanosystems, Canada; Leung et al, 2015). After preparation, LNP formulations were dialyzed into IX PBS (pH 7.4) for 2 hours in 10K MWCO Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, MA).
• the size and zeta potential of LNP formulations were characterized by using Zetasizer Nano-ZS (Malvern Instruments MA). Each formulation was 10-fold diluted in 0.1X PBS buffer for size measurement and 40-fold diluted in 0.1X PBS for zeta potential measurement. Dynamic light scattering was performed on diluted samples at 25°C with 173° and the reported z-average diameter is a mean of three measurements.
• mRNA Encapsulation efficiency was evaluated by low range Quanti-iT RiboGreen RNA reagent assay (Thermo Fisher Scientific, MA). Each LNP sample was diluted into TE buffer down to a mRNA concentration of 0.2 ng/ ⁇ L. Aliquots of each LNP working solution was further diluted 1 : 1 in TE buffer (measuring unencapsulated mRNA) or 1:1 in TE buffer with 4% Triton-XlOO (measuring total mRNA- both encapsulated within LNPs and unencapsulated free mRNA) in a 96- well plate.
• TNS assays A series of buffers with pH ranging from 2.5 to 11 (pH 2.5, pH 3, pH 3.5, pH 4, pH 4.6, pH 5, pH 5.5, pH 5.8, pH 6, pH 6.5, pH 7, pH 7.5, pH 8, pH 8.5, pH 9, pH 9.5, pH 10, pH 10.5, pH 11 ) were prepared by adjusting the pH of a buffer solution consisting of 10 mM HEPES, 10 mM MES, 10 mM ammonium acetate, 130 mM NaCl with 1 N HC1. Also, 90 ⁇ L of each buffer solution was added to a 96-well plate.
• HEK-293 cells were cultured with Dulbecco’s Modified Eagle Medium containing 10% FBS and 1% penicillin streptomycin.
• NuLi-1 cells (ATCC CRL-4013) were cultured in flasks pre-coated with 60 pg/mL solution of human placental collagen type IV (Sigma Aldrich, MO) and grown in bronchial epithelial growth medium (BEGM) supplemented with SingleQuot additives from Lonza (BEGM Bullet Kit, reference CC-3170) and 50 pg/mL G-418. All cell lines were maintained as monolayer cultures at 37 °C and 5% C0 2 .
• Cells were seeded in 96-well plates at a cell density of 12,500 cells/well and grown for 24 hours at 37 °C and 5% CO2. Then 10 ⁇ L of LNP at a 10 ng EGFP mRNA/m L concentration was added to cells in 0.2 mL cell culture media for 24 hours. After, the cell culture media was removed, and cells were washed with IX PBS. To detach the cells, 100 m L of 0.25% trypsin-EDTA solution was added to each well and incubated at 37 °C for 8-10 minutes.
• mice Female, 6-8 weeks were anesthetized under a continuous flow of 2% isoflurane, and approximately 50 ⁇ L of LNP containing 1.5 pg of FLuc mRNA/ ⁇ L in PBS were administered intratracheally. After 6 hours, mice were intraperitoneally (i.p.) injected with D-Luciferin solution (30 mg/ml) to reach 150 mg Luciferin/kg body weight. After 15 minutes, mice were sacrificed and the lungs were carefully harvested and imaged by an In Vivo Imaging System (IVIS), with bioluminescence setting and a luminescent exposure time of 60 sec. Quantification of luminescence (in radiance [p/sec/cm 2 /sr]) was performed with Living Image 4.3 software (PerkinElmer).
• IVIS In Vivo Imaging System
• LNP formulations were prepared by varying the N/P ratio between 6 to 200.
• LNP formulations were composed of DLin-MC3-DMA, a phosphatidylcholine (1,2-distearoyl-sn- glycero-3-phosphocholine, DSPC), cholesterol, and a PEG-lipid (polyethylene glycol- dimyristolglycerol, PEG-DMG) at a single molar ratio of 50:10:38.5:1.5, respectively (as previously described in Jayaraman et al., 2012).
• N/P ratios 6, 15, 30, 50, 100, and 200 were achieved by varying the relative amount of lipid composition added to the mRNA (10 ng/pl).
• LNPs consist generally of four lipid components: ionizable lipid, phospholipid, PEG- lipid, and cholesterol.
• the different types and amount of lipids may affect the transfection efficacy of LNP formulations (Kauffman et al, 2015).
• One-factor-at-a-time design methods have been employed in several studies to investigate the effect of formulation composition on the efficacy of each LNP formulation (Belliveau et al, 2012; Akinc et al, 2009). However, this approach does not account for potential second-order interactions between composition parameters, which makes it less desirable for optimization of LNP formulations.
• the size and zeta potential of the LNP formulations did not show significant changes after 14 days of storage in 4 °C, which indicated that the size and surface charge of all formulations remained stable for at least 2 weeks (FIGS. 18A & 18B).
• the encapsulation efficiency of the formulations was evaluated by RiboGreen assay. Most of the formulations possessed a high encapsulation efficiency greater than 80%, except for F12 which showed 49% encapsulation efficiency (FIG. 18C).
• the pKa of LNPs may be critical for endosomal escape and has been implicated as a correlator for in vivo efficacy of gene therapy (Jayaraman et al., 2012). Therefore, the pKa of LNP formulations loaded with EGFP mRNA was measured using the TNS assay, and the pKa ranged from 5.74 (F15) to 6.11 (F14) (FIG. 18D).
• FNP formulations For clinical use, they must be able to be aerosolized for pulmonary delivery without significant instability. Towards that end, the effects of nebulization on the FNP formulations was investigated and the formulations that retained high intracellular uptake in vitro following nebulization were identifed. FNP formulations were aerosolized by the Aerogen Solo nebulizer and the potency of each nebulized formulation was evaluated in human embryonic kidney HEK-293 and human bronchial epithelial NuFi-1 cell lines.
• the size of the FNP formulations ranged from 100.9 nm (F12) to 1480.7 nm (F7) and showed a significant increase compared to the pre-nebulized FNP formulations, while the zeta potential showed no significant changes amongst all formulations (FIGS. 19A-19C). It is worth noting that F8 had the smallest change in size upon nebulization, and F7 showed the largest change in size after nebulization.
• the encapsulation efficiency of the FNP formulations significantly decreased after nebulization, which indicated that the mRNA potentially leaked from the FNPs upon the nebulization process.
• the encapsulation efficiency of nebulized FNP formulations ranged from 15.5% (F12) to 79.9% (F17).
• Intracellular uptake of LNP formulations in HEK-293 and NuLi-1 cells Intracellular uptake of LNP formulations in HEK-293 and NuLi-1 cells.
• the intracellular uptake of pre- and post-nebulized FNP mRNA formulations was assessed using flow cytometry by measuring percent GFP expression and fluorescence intensity in HEK-293 and NuFi-1 cell lines.
• composition of LNP formulations influenced their physicochemical properties (size, zeta potential, and encapsulation efficiency) before and after nebulization. It was found that pre-nebulized dispersions had a particle size that was dependent on the molar ratio of PEG-lipid used. In these pre-nebulized formulations, it appeared that the type of PEG- lipid used did not influence particle size in a significant way. In contrast, the nebulized dispersions were significantly influenced by the type of PEG-lipid used in the formulation.
• the zeta potential of the formulations was also primarily driven by the type of PEG-lipid selected.
• a statistically significant trend of increasing LNP zeta potential was observed with an increasing molar ratio of PEG-lipid for either pre- nebulized or nebulized LNP formulations, independent of the other formulation parameters (FIGS. 24A & 24C).
• this significant trend was primarily related to the type of PEG-lipid used, where formulations with DSPE-PEG showed a higher zeta potential irrespective of aerosolization process (FIGS. 24B & 24D).
• PEG-lipid molar ratio negatively influenced the intracellular uptake of LNPs before and after nebulization.
• Formulations of the mRNA loaded LNPs must balance several performance measures, such as transfection efficiencies and nanoparticle stability.
• PEG-lipids were used to impart physical stability on the nanoparticle dispersion.
• PEGylation can significantly influence transfection efficiencies (Otsuka et al., 2003; Mishra et al., 2004; Osman et ah, 2018).
• the PEG-lipid molar ratio significantly and negatively affected the intracellular uptake of LNPs both before and after nebulization.
• LNP formulations can be more rapidly and easily identified that possess the optimal properties to facilitate effective aerosolized delivery of mRNA. While this work focused on the delivery of mRNA towards the treatment of pulmonary diseases, the DOE strategy could be broadly applied to discover LNP compositions and their properties that promote enhanced delivery of nucleic acid therapeutics for different indications.
• DOTAP 1,2- dipalmitoyl-sn-glycero-3-phosphocholine
• DODAP 1,2- dipalmitoyl-sn-glycero-3-phosphocholine
• DSPC 1,2- dipalmitoyl-sn-glycero-3-phosphocholine
• DSPC 1,2- dipalmitoyl-sn-glycero-3-phosphocholine
• DSPC 1,2- dipalmitoyl-sn-glycero-3-phosphocholine
• DSPC 1,2- dipalmitoyl-sn-glycero-3-phosphocholine
• DSPC 1,2-distearoyl-sn-glycero-3- phosphocholine
• DSPC 1,2-distearoyl-sn-glycero-3- phosphocholine
• DOPE Delta 9 cis
• N- (methylpolyoxyethyleneoxycarbonyl)-l,2-dimyristoyl-sn-glycero- 3-phosphoehtanolamine (DMPE-PEG 2000) was purchased from NOF Corporation, Tokyo, JP. Cholesterol was purchased from Sigma Aldrich, MO. Ethanol (molecular grade) was purchased from Decon Laboratories, Inc., PA. Edit-R Cas9 Nuclease mRNA with EGFP reporter (reference CAS 11860) was purchased from Horizon Discovery Dharmacon Inc., Chicago, IL, USA.
• Lipid nanoparticles containing Edit- R Cas9 Nuclease mRNA were prepared by combining an aqueous phase (mRNA diluted in 50 mM sodium acetate citrate buffer, pH 4.0) and an organic phase containing ethanol and lipids according to each formulation (Table 1) using a microfluidic mixer (Precision Nanosystems, Canada; Leung et al., 2015). Flow ratio was 3:1 (aqueous:organic) and the nitrogen to phosphorus (N/P) ratio was 6. After preparation, LNP formulations were dialyzed into IX PBS (pH 7.4) for 2 hours in 10K MWCO Slide- A-Lyzer dialysis cassettes (Thermo Fisher Scientific, MA).
• the size and zeta potential of LNP formulations were characterized by using Zetasizer Nano-ZS (Malvern Instruments MA). Each formulation was 10-fold diluted in 0.1X PBS buffer for size measurement and 40-fold diluted in 0.1X PBS for zeta potential measurement. Dynamic light scattering was performed on diluted samples at 25°C with 173° and the reported z-average diameter is the mean of three measurements.
• mRNA Encapsulation efficiency was evaluated by low range Quanti-iT RiboGreen RNA reagent assay (Thermo Fisher Scientific, MA). Each LNP sample was diluted into TE buffer down to a mRNA concentration of 0.2 ng/ ⁇ L. Aliquots of each LNP working solution was further diluted 1 : 1 in TE buffer (measuring unencapsulated mRNA) or 1:1 in TE buffer with 4% Triton-XlOO (measuring total mRNA- both encapsulated within LNPs and unencapsulated free mRNA) in a 96- well plate.
• HEK-293 cells were cultured with Dulbecco’s Modified Eagle Medium containing 10% FBS and 1% penicillin streptomycin.
• NuLi-1 cells (ATCC CRL-4013) were cultured in flasks pre-coated with 60 pg/mL solution of human placental collagen type IV (Sigma Aldrich, MO) and grown in bronchial epithelial growth medium (BEGM) supplemented with SingleQuot additives from Lonza (BEGM Bullet Kit, reference CC-3170) and 50 pg/mL G-418. All cell lines were maintained as monolayer cultures at 37°C and 5% C0 2 .
• the size and zeta potential of the LNP formulations showed changes after 7 days of storage at 4 °C, with an increase in particle size and changes in zeta potential for some formulations (FIGS. 28 A & 28B).
• the encapsulation efficiency of the formulations was evaluated by RiboGreen assay according to the manufacturer protocol (Thermo Fisher Scientific, MA). Half of the formulations possessed a high encapsulation efficiency greater than 80% (F3, F4, F9, F10, FI 1, F13, F15, F17, F18, and F20), and F16 demonstrated an encapsulation efficiency of 70.28%.
• the other formulations demonstrated encapsulation efficiencies equal or lower than 50% (FIG. 28C).
• Poly (ethylene glycol) monomethyl ether MW 5000 kDa, mannitol, sucrose, trehalose, and leucine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Low molecular weight chitosan MW 15 kDa, was obtained from Polysciences Inc., USA. Nuclease-free water, Dulbecco’s Modified Eagle’s Medium (DMEM), Opti-MEM, and diethyl ether were obtained from Thermo Fisher Scientific Inc. (Waltham, MA, USA).
• pSpCas9(BB)- 2A-GFP was a gift from Feng Zhang (Addgene plasmid # 48138; http://n2t.net/addgene:48138; RRID:Addgene_48138; Ran et al, 2013).
• the frozen samples were collected in a stainless-steel container filled with liquid nitrogen and transferred into a -80 °C freezer to remove extra liquid nitrogen.
• a VirTis Advantage Lyophilizer (VirTis Company Inc., Gardiner, NY) was used to remove the water.
• the samples were kept at -40 °C for 40 h for primary drying, and the temperature was slowly increased to 25 °C over 650 min, and then kept at 25 °C for another 6 h to dry for secondary drying. The pressure was kept at 300 mTorr during the drying process.
• Four lipid nanoparticle dry power formulations were also formulated with mannitol, sucrose, and trehalose at a concentration of 20% (w/v).
• SEM Scanning electron microscopy
• Aerodynamic Particle Size Distribution by next generation impactor was detected by the Next Generation Impactor (NGI, MSP Corporation, MN, USA). Dry powders were loaded into size 3 hypromellose (HPMC) capsules, a gift from Capsugel Inc. (Morristown, NJ, US). Dry powder formulations were aerosolized through a Monodose RS01 high resistance DPI (Plastiape, Osnago, Italy) or a Spiriva HandiHaler. Aerosols were produced at an air flow rate of 60 L/min over four seconds for to achieve an inhalation volume of 4 L.
• NPI Next Generation Impactor
• the pressure was generated by a High Capacity Pump (model HCP5, Copley Scientific, Nottingham, UK) and controlled by a Critical Flow Controller (model TPK 2000, Copley Scientific, Nottingham, UK).
• NGI plates were coated with 1% glycerol in ethanol and air dried before each ran. Each dry powder sample was ran in triplicate. After aerosolization, dry powders deposited in the capsule, device, induction port (IP), and stages 1 - MOC were dissolved in Phosphate-Buffered Saline (PBS) pH 7.4 and measured by Tecan Infinitel 200 PRO multimode microplate reader (Tecan Systems, Inc., San Jose, CA, USA).
• PBS Phosphate-Buffered Saline
• GSD Geometric standard deviation
• MMAD mass median aerodynamic diameter
• FPF% fine particle fraction%
• the SSA of dry powders were analyzed by Monosorb rapid surface area analyzer model MS-21 (Quantachrome Instruments, Boynton Beach, FL) by single-point BET method. Samples were outgassed with nitrogen gas at 20 psi at 37 °C overnight to remove surface impurities. A mixture of nitrogen/helium (30:70 v/v) was used as the adsorbate gas.
• Transfection efficiency The transfection efficiency of the DNA plasmid (pSpCas9(BB)-2A-GFP) and LNP-mRNA was evaluated in HEK293 cells.
• 5 x 10 3 of HEK293 cells were seeded in 100 ⁇ L of DMEM media in each well of 96-well plates and incubated for 24 h to allow complete adherence. After incubation, the media was removed, and Opti-MEM reduced serum media was added to the cells. 10 ⁇ L of reconstituted formulation was added to cells cultured in media with different pH 6.5. After incubation for 24 h, the transfection efficiency was evaluated by flow cytometry.
• Lipid nanoparticles containing enhanced green fluorescent protein (EGFP) mRNA were prepared by combining an aqueous phase (mRNA diluted in 100 mM sodium acetate citrate buffer, pH 3.0) and an organic phase containing ethanol and lipids according to each formulation (Table 5) using a microfluidic mixer (Precision Nanosystems, Canada; Leung et al., 2015). After preparation, LNP formulations were dialyzed into IX PBS (pH 7.4) for 2 hours in 10K MWCO Slide-A-Lyzer dialysis cassettes (Thermo Fisher Scientific, MA).
• aqueous phase mRNA diluted in 100 mM sodium acetate citrate buffer, pH 3.0
• organic phase containing ethanol and lipids according to each formulation (Table 5) using a microfluidic mixer (Precision Nanosystems, Canada; Leung et al., 2015).
• LNP formulations were dialyzed into IX PBS (pH 7.4) for 2 hours in 10K
• the particle size ranged from 200.4 ⁇ 9.2 nm (F15) to 536.0 ⁇ 198.8 nm (F21), while the particle size of Suc-Leu DP ranged from 206.8 ⁇ 11.1 nm (F22) to 326.4 ⁇ 21.6 nm (F28).
• the smallest particle size was observed in F29 and the formulation showed largest particle size is F35.
• the particle size ranged from 202.9 ⁇ 4.5 nm (F36) to 376.3 ⁇ 47.6 nm (F42). In sum, a trend of an increasing nanocomplex size was observed with a decreasing concentration of cryoprotective agents. In contrast, no obvious trend was observed in terms of the zeta potential of DP formulations.
• FIG. 32 showed the transfection efficiency of the reconstituted formulations data normalized to the unprocessed nanocomplexes. It was found that the either high or low concentration of the cryoprotective agent was not able to protect the potency of nanocomplexes from the TFF/lyophilization or reconstitution steps.
• cryoprotective agent Based on these screening assays, it was found that a higher concentration of cryoprotective agent resulted in less aggregation of the nanocomplexes after reconstitution (i.e. lower particle size changes) however the highest transfection efficiency was found with formulations containing cryoprotectant concentrations ranging from 0.5-3%. Thus, six formulations (F3, F10, F17, F24, F31, and F38) containing 3% of cryoprotective agents were selected as lead formulations for further investigation (FIG. 33).
• Aerodynamic performance of refined dry powder formulations in RS01 Monodose DPI was used to evaluate the aerodynamic performance of refined dry powder formulations which were aerosolized by the low resistance RS01 Monodose DPI (flow rate 60L/min). As shown in FIG. 36, F3 and F10 rendered a higher deposition below stage 2 (4.46 microns aerodynamic cutoff) compared to other formulations, which indicated a better aerodynamic particle size distribution of F3 and F10. Based on the deposition profile, MMAD, FPF%, and EF% were calculated and summarized in Table 8.
• F3 and F10 demonstrated a MMAD of 4.8 pm and 4.6 pm, respectively, which indicated a better potential for dry powder particle deposition in lung compared to other formulations which had MMADs larger than 5 pm. Furthermore, even though the EF% of F3 (74.2%) and F7 (71.5%) were lower than that of other formulations, F3 and F10 demonstrated a relatively higher FPF% ( ⁇ 5pm) of 44.5% and 44.2% than other formulations, respectively. Based on these results, F3 and F10 were identified as the formulations suitable for inhalation and were tested further.
• both formulations had a significant higher EF% and FPF%, and a lower MMAD at the flow rate of 60L/min compared to that at the flow rate of 45 L/min, which indicated a flow rate-dependent aerodynamic performance of F3 and F10 in these devices.
• HandiHaler DPI rendered a higher EF%, but a larger MMAD, for either F3 or F10 compared to that of RS01 Monodose DPI, which indicated that the aerodynamic performance of both formulations was also inhaler type dependent.
• TFF lipid nanoparticle-mRNA (LNP) dry powder formulations Size of TFF lipid nanoparticle-mRNA (LNP) dry powder formulations.
• LNP formulations consisting of ionizable lipids, phospholipids, cholesterol, poly-(ethylene) glycol (PEG)-lipid), and mRNA encoding EGFP were formulated into dry powder by TFF with different excipients at a concentration of 20% (w/w): mannitol, sucrose, and trehalose were employed. After TFF and lyophilization, the dry powder formulations were reconstituted in distilled water and the LNP particle size were measured by DLS. As shown in FIG.
• PLC Polyethylene glycol 2000-hydrazone-C18
• Lipofectamine RNAiMAX Transfection Reagent Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), streptomycin/penicillin, FluoSpheresTM amine-modified polystyrene microspheres, and HEPES buffer were from Invitrogen (Carlsbad, CA).
• TopFluor ® Cholesterol and l,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were from Avanti Polar Lipids (Alabaster, Alabama, USA).
• TNF-a siRNA was purchased from Integrated DNA Technologies (Coralville, Iowa, USA) with sequence (5'-GUCUCAGCCUCUUCUCAUUCCUGCT-3' (SEQ ID NO: 1), anti-sense: 5 AGCAGGAAUGAGAAGAGGCUGAGACAU-3 ' (SEQ ID NO: 2)) TNF-a ELISA kit was from BioLegend (San Diego, CA).
• siRNA incorporated SLNs 100 pi of 20 pM siRNA in water was diluted with 400 ⁇ L of water and then added to 680 ⁇ L of 2.56% (v/v) DOTAP in chloroform and stirred vigorously for 30 min, followed by the addition of 1.3 mL of methanol stirred for 1 h.
• the siRNA/DOTAP complexes were extracted with chloroform from the mixture by phase separation.
• Lecithin (3.2 mg), cholesterol (1.6 mg), and PHC (2 mg) were dissolved in 0.5 mL of chloroform and mixed with the siRNA/DOTAP complexes. The mixture was dried under nitrogen gas and then re-dissolved in 500 ⁇ L of THF before adding dropwise to 5mL of water.
• a TopFluor cholesterol solution (0.25% w/v in chloroform) was added to the lecithin mixture before mixing with the siRNA/DOTAP complexes.
• the size, polydispersity index (PDI), and zeta potential of the resultant SLNs were measured by dynamic light scattering (DLS) using a Malvern Zeta Sizer Nano ZS (Westborough, MA).
• Lyophilization cycle was -40 °C shelf temperature for 20 h, ramped to 25 °C over 20 h, then hold at 25 °C for another 20 h with pressure blow 100 mPa using a VirTis Advantage Bench Top Lyophilizer (Gardiner, NY, USA).
• the mannitol to SLNs ratio was determined by a freeze- and-thaw experiment. Briefly, 1 mL of the SLNs in suspension were mixed with different amount of mannitol and froze at -80 °C for 2 h and then thawed at room temperature before measuring the particle size and PDI.
• the spray-dried nanoparticle powder was prepared by dissolving mannitol into the nanoparticle suspension at 4.08 mg/mL, which was then dried using a Biichi B-290 Mini Spray Dryer (Flawil, Switzerland) with a ⁇ 0.5 mm two-fluid nozzle.
• the flow of the aerosolization gas was 29 L/min (nitrogen)
• the aspirator was set to 100 psi
• the inlet temperature was 90 °C
• the outlet temperature was 65 °C
• the suspension feed rate was 3 mL/min.
• the powder was stored in a vacuum desiccator in dark until analysis.
• the powder was stored in a vacuum desiccator in dark until further analysis.
• An ethanol in water solution (50%, v/v) was chosen as the resuspension media since the fluorescence signal was relatively weak in pure water.
• Nanoparticle diffusion in stimulated mucus The diffusion of SLNs and polystyrene beads were compared in simulated mucus was measured using a previously developed assay (Leal et al, 2018). Mucin was dissolved in 20 mM HEPES buffer to make 2% (w/v) solution and gently agitated for 30 min, then 100 ⁇ L of the simulated mucus was transferred to the top compartment in the polyester membrane Corning® Transwell insert with 3.0 pm pore size (Coming, NY) against 600 ⁇ L of 20 mM HEPES buffer in the bottom compartment, and the Transwells were left at room temperature.
• the pore size was selected to ensure the particle can move through the membrane while retain the mucin gel during the time course of the experiment (Norris and Sinko, 1997).
• 10 pi of reconstituted SLNs or polystyrene beads (as a control) were gently added to the top compartment.
• the bottom HEPES buffer was collected and replaced with fresh HEPES buffer every hour for 5 h.
• Wells without mucin gel was used as a control.
• the particle amount in collected eluates was determined from the fluorescence intensity based on a 6 points linear calibration curve.
• ELISA TNF-a SLN powder (100 mg) was resuspended in 5 mL of serum-free media and then filtered with 3.2 pm PTFE filter. J774A.1 macrophage cells (American Type Culture Collection, Manassas, VA) were seeded in a 96-well plate (7000 cells/well). After overnight incubation, the medium was replaced by 150 ⁇ L/well of the suspension. After 4 h, 150 ⁇ L of media with 20% FBS was added, and the cells incubated for forty-four (44) additional hours. The medium was then replaced with 300 ⁇ L/well of medium containing LPS at 300 ng/mL and incubated for 4 h before measuring the TNF-a concentration by a BioLegend ELISA kit.
• TFFD is a fast- freezing process followed by lyophilization. Dry powder prepared by TFFD is porous with a high surface area. The method has been successfully applied to small molecules (Zhang et al., 2012; Overhoff et al., 2008; Overhoff et al., 2007), proteins (Engstrom et al., 2008), and vaccines adjuvanted with insoluble aluminum salts (Thakkar et al., 2017; Li et al., 2015). In addition, the fluffiness and brittleness of the powder give it excellent aerosol properties for pulmonary drug delivery.
• Pulmonary delivery of small molecules (Patlolla et al., 2010; Nemati et al., 2019; Patil-Gadhe et al., 2016) and nucleic acid- based agents (Hyde et al., 2014; Deshpande et al., 2002) has proven feasible using lipid-based particles as carriers.
• Both spray drying (Nemati et al., 2019) and freeze-drying (Lball et al., 2017) have been used to prepare dry powder formulation of SLNs.
• spray drying Nemati et al., 2019
• freeze-drying Lball et al., 2017
• aerodynamic properties of ethambutol-loaded SLN dry powder prepared by spray drying were not favorable for deep lung delivery, due to its large particle size (Nemati et al., 2019).
• SLNs Since only particles with the size between 1 pm to 5 pm can be deposited to the deep lung, SLNs with diameters in the range of 100-200 nm are too small and will be exhaled after inhalation (Rahimpour and Hamishehkar, 2012). Therefore, SLNs require excipient(s) to act as a carrier and cytoprotectant(s) for dry powder formation. In this study, the feasibility of applying TFFD to SLNs for pulmonary delivery was tested. The SLNs were prepared by the solvent evaporation method as previously described (Aldayel et al., 2018). They were prepared with lecithin, cholesterol, and PHC, with or without siRNA complexed with a cationic lipid.
• the resultant SLNs were approximately 100-150 nm in diameter (measured by DLS), relatively uniformly distributed, and spherical.
• the siRNA-free SLNs were then subjected to TFFD or spray-drying and the powders generated were compared.
• SLNs encapsulated with TNF-a siRNA were then subjected to TFFD.
• the dry powder of the TNF-a siRNA-SLNs was characterized, its aerosol properties measured, as well as the function of the TNF-a siRNA- SLNs after they were subjected to TFFD and reconstitution and the ability of the TNF-a siRNA-SLNs to permeate through simulated lung mucus.
• the PDI of the SLNs did not change after they were subjected to TFFD and reconstitution, although it was increased after subjected to SD and reconstitution.
• the mechanism underlining the increase in particle size is not known, but freezing stress (Chung et al., 2012) as well as stress during the drying step and particle excipient interaction may have contributed to the particle size increase (Niu and Panyam, 2017).
• the powders were then characterized by examining their morphology and specific surface area. As shown in FIG. 39, the TFFD powder demonstrated porous texture, while the SD powder showed beads-like microstructures.
• siRNA-encapsulated SLNs Preparation and characterization of thin-film freeze-dried powder of siRNA-encapsulated SLNs.
• siRNA was mixed with a biocompatible cationic lipid, DOTAP, at a N to P ratio of 12 to 1 and then mixed with other ingredients followed by solvent evaporation as previously described.
• the resultant siRNA- SLNs had a slightly larger particle size compared to the siRNA-free SLNs (Table 14).
• the siRNA-SLNs in suspension were mixed with mannitol at ratio of 1:30, w/w, and subjected to TFFD.
• the powder as shown in FIG. 41A were fluffy with porous texture.
• the size of the siRNA-SLNs increased slightly after they were subjected to TFFD and reconstitution.
• FIG. 4 IB showed the aerosol performance characteristics of the siRNA-SLN powder prepared by
• TFFD TFFD.
• the siRNA-SLN powder had a high FPF% (Table 15), and high deposition in stages representing the deep lung (FIG. 4 IB).
• the main factor for delivery to alveoli of the lung is the aerodynamic particle size.
• Thin- film freeze-dried siRNA-SLN powder demonstrated smaller MMAD, higher FPF%, and higher deposition to the NGI stages corresponding to alveoli than previously published methods (Nemati et al., 2019; Ohashi et al., 2009), suggesting that TFFD is ideal for generating dry power of siRNA-SLNs for aerosol delivery.
• MMAD geometric standard deviation
• the TNF-a siRNA-SLNs after subjected to TFFD and reconstitution were as effective as those before TFFD in downregulating TNF-a release from the cells, demonstrating that TFFD can be successfully applied to transform the siRNA-SLNs from a liquid suspension to dry powder without compromising the functionality of the siRNA.
• siRNA-SLNs Diffusion of the siRNA-SLNs across simulated mucus.
• siRNA-SLNs delivered to the lung to have access to live cells they need to permeate through the mucus layer.
• a mucus penetration assay was performed using a system consist of a Transwell permeable support with or without a simulated mucus (Norris and Sinko, 1997; Desai et al., 1991).
• the SLNs in suspension were added gently on the mucus, in the center of the well without disturbing the mucus, and the particle concentration in the other side of the Transwell was quantified at different time points.
• siRNA-SLNs can permeate the mucus in the lung after they are aerosolized into the lung as thin- film freeze-dried powder.
• the TFFD powder of siRNA-SLNs can be potentially used for pulmonary delivery of the siRNA to the lung to treat pulmonary diseases, such as asthma and other chronic inflammatory diseases, using siRNA specific to key proinflammatory cytokines such as TNF-a.
• the siRNA does not have to be TNF-a siRNA, and in fact, it is expected that other nucleic acid- based agents, such as mRNA, shRNA, plasmid DNA, minicircle DNA, DNA oligos, may also be formulated into the SLNs or lipid nanoparticles similar to the SLNs used in this study.
• the nanoparticles do not need to be lipid-based; nanoparticles of polymer-based or made of inorganic nanoparticles may also be converted from a liquid suspension to dry powder using TFFD for aerosolization.
• nanoparticles are commonly used as carriers to protect nucleic acid-based agents and to improve their uptake by target cells.
• nucleic acid-based agents are specially engineered to be stable and/or can be taken up by target cells without the help of the nanoparticles, then they can be directly converted into dry powder with good aerosol properties using TFFD.
• the therapeutic and/or diagnostic agents encapsulated into the nanoparticles do not have to be nucleic acid-based. Small molecules, proteins, and even bacteria and viruses may be carried by the nanoparticles.
• any potential therapeutic and diagnostic agents may also be mixed with nanoparticles before they are subjected to TFFD.
• Freeze drying of colloidal suspension has been described in detail before, and it was shown that the increase in the size of the colloidal nanoparticles caused by the bulking agent is universal in stable colloidal systems (Lintingre et al, 2016). This may explain the increase in the hydrodynamic diameters of the SLNs, encapsulated with siRNA or not, after they were subjected to TFFD. The ratio of SLNs to excipients plays a significant role in affecting the particle size and polydisperse index (PDI) of the SLNs. Freeze drying of colloidal suspension is a multiple-step process, and it is rather difficult to describe such a process.
• the particle aggregation caused by freezing is mainly attributed to ice crystallization, which pushes particles to a small area with high freezing stress.
• the excipient(s) serve as a water surrogate, stabilizing the particles by establishing hydrogen bonds with the particle surface (Abdelwahed et al, 2006).
• TFFD technology is unique in two aspects: First, the cooling rate is in the range 500-1000 K/sl7, compared to shelf freezing where the cooling rate is on the scale of 1 to 10 K/min. The faster cooling results in smaller ice crystals. Second, the TFFD process creates thin films with thickness below one millimeter, and the free space in the thin films provides channels for water to travel in the sublimation process.
• the siRNA-solid lipid nanoparticles were engineered by encapsulating TNF-a siRNA complexed with a cationic lipid into solid lipid nanoparticles prepared with lecithin, cholesterol, and a polyethylene glycol (2000)-hydrazone-stearic acid (Cl 8) derivative by nanoprecipitation.
• the nanoparticles were fluorescently labeled with TopFluor cholesterol.
• mannitol was added to the nanoparticle suspension, and the suspension was then freeze-dried. The aerosol performance of the dry powder was examined using a next generation impactor (NGI).
• NTI next generation impactor
• NGI next generation impactor
• the TNF-a siRNA solid lipid nanoparticles were spherical. Their particle size and polydispersity Index were 118 + 7 nm and 0.16 ⁇ 0.01. In cell culture, the TNF-a siRNA solid lipid nanoparticles significantly downregulated the expression of TNF-a by J774A.1 mouse macrophages treated with lipopolysaccharide (FIG. 44). The NGI data demonstrated the dry powder of the nanoparticles has good aerosol performance with a fine particle fraction (FPF) of 78.5% (FIG. 45). The TNF-a siRNA solid lipid nanoparticles were spherical. Their particle size and polydispersity Index were 118 +7 nm and 0.16 +0.01. (FIG. 46).
• Dry Powder Formulations of SLN Physical appearance of dry powder formulations of SLN shown in FIG. 47. The specific surface area of spray dried SLN powder was 0.92+0.11 m 2 /g whereas the freeze-dried powder was 19.34+2.5 m 2 /g, both determined by Brunauer-Emmett-Teller (BET).
• BET Brunauer-Emmett-Teller
• TNF-a siRNA solid lipid nanoparticle formulation was able to successfully inhibit TNF-a production by macrophages in culture and alleviated chronic inflammation in mouse model.
• a dry powder of the nanoparticles showed good aerosol performance for pulmonary delivery.
• a single colony of Escherichia coli DH5a (Invitrogen, Carlsbad, CA) was inoculated into 3 mL Loria Bertani broth (LB) medium (Invitrogen) starting culture and then transferred to 100 mL LB medium and incubated overnight at 33°C with shaking.
• the bacteria were harvested by centrifugation at 2000 ref for 15 min and washed with cold phosphate-buffered saline (PBS, pH7.4, 10 mM) once. After centrifugation, the bacteria were resuspended to a solution with 10% (w/v) sucrose to the original volume.
• PBS cold phosphate-buffered saline
• ⁇ L of the bacterial suspension (0.7-5 x 10 8 colony forming units (CFU) per ml) was added drop wise using a 21 Gauge needle attached to a syringe to the bottom of a 20 mL glass vial that was pre-cooled with dry ice.
• the glass vial with the frozen thin-films of bacteria was then capped and placed at room temperature to thaw or stored at -80°C until further testing. Shelf freezing was used as a control.
• 250 ⁇ L of the bacterial suspension was dispensed in a 20 mL glass vial and then frozen at -20°C for 2 h.
• Table 17 A comparison of bacterial viability after they were subjected to shelf freezing or thin-film freezing.
• bacteria suspended in 10% sucrose was subjected to a standard lyophilization cycle (i.e. sample was dried with a Virtis Advantage freeze dryer (Warminster, PA); pressure was ⁇ 10 mbar; shelf temperature was -40°C for 24 h, ramped to 25 °C in 24 h, and then hold at 25 °C for 24 h, or Method A in Table 18).
• the dry powder was then reconstituted with LB medium and the number of live bacteria in the suspension was determined by the plate assay after serial dilution with sterile PBS (pH 7.4, 10 mM).
• FIG. 51 shows that bacterial dry powder prepared with thin-film freeze-drying is different from that prepared by shelf freeze-drying.
• Table 20 shows results of freeze and thaw experiments.
• Cells were centrifuged on 4000 RPM for 30 min and then resuspended in 10% w/v sucrose solution.
• 100 ⁇ L suspension underwent serial dilution directly.
• 500 ⁇ L of the suspension was placed on -20 °C fridge for 30 min and then warmed to RT.
• 250 ⁇ L of the suspension was dropped to a 20 mL glass vial that was pre-cooled in dry ice-ethanol bath, then warmed to RT directly.
• Table 20 Results of freeze and that experiments.
• bacteria were performed using thin-film freezing on a stainless-steel drum and water was sublimed from the frozen thin-films using a Virtis Advantage Pro lyophilizer (Warminster, PA).
• a single colony of E. coli DH5a with ampicillin resistant pUC19 vector (Invitrogen, Carlsbad, CA) was inoculated into 5 mL Miller Loria Bertani broth (LB) medium (Invitrogen) starting culture overnight and then transferred to 100 mL LB medium and incubated at 37°C with shaking until OD600 reaches 0.4.
• the bacteria were harvested by centrifugation at 4300 ref for 5 min at ambient temperature.
• the bacteria were resuspended to cryoprotectant cocktails at 10% of the original culture volume.
• 1000 ⁇ L of the bacterial suspension (0.1-2 xlO 9 colony forming units (CFU) per ml) was added drop wise using a 21 Gauge needle attached to a syringe to the rotating stainless drum pre-cooled to -40°C.
• the frozen films were collected to a 5 mL amber glass vial stored at -80°C until lyophilization using cycle shown in Table 21.
• the number of live bacteria in the suspension, before or after subject to the TFFD process, was determined using the standard serial dilution method with LB medium and spread to LB agar plates.
• the b-galactosidase gene-encoding plasmid DNA pCMV-b was from the American Type Culture Collection (ATCC, Manassas, VA), It was constructed based on pUC19 plasmid capable of expressing E. coli beta-galactosidase (b-Gal) under the control of different viral promoters in mammalian cells (MacGregor et al. , 1989).
• E. coli DH5a competent cells and LB broth were from Invitrogen (Carlsbad, CA).
• the 1,4-dioxane and /er/ -butanol, Tris-EDTA (TE) buffer, and ampicillin were from Fisher Scientific (Fair Lawn, NJ).
• Agarose was from Amresco (Atlanta, GA). Polysorbate 20, lactose monohydrate, and methanol anhydrate were from Sigma-Aldrich (St. Louis, MO). Quant-iTTM PicoGreenTM dsDNA Assay Kit was from Thermo Scientific (Waltham, MA). Size #3 hydroxypropyl methylcellulose capsules were from Quali-V-I capsules (Qualicaps US, Whitsett, NC). ii. Plasmid Preparation
• the pCMV-b plasmid was transformed into E. coli DH5a under selective growth conditions and then amplified and purified using a QIAGEN Midiprep Kit (Valencia, CA). Large scale plasmid preparation was performed by QIAGEN Plasmid Maxi kit. The plasmid was evaluated using agarose gels and Nanodrop 2000 Spectrophotometers from Thermo Scientific (Waltham, MA) iii.
• Table 23 List of plasmid compositions and TFF parameters.
• TFF process and lyophilization was done as previously described (Li et al, 2015; Sahakijpijam et al, 2020a; Moon et al, 2019; Sahakijpijam et al, 2020b). Briefly, 0.25 mL of sample was dropped through a 21 -gauge syringe dropwise onto a rotating cryogenically cooled stainless-steel surface (-80 ⁇ 10 °C). To form frozen thin-films, the speed at which the cryogenic ally cooled steel surface of the drum rotated was controlled at 5-7 rpm to avoid the overlap of droplets. The frozen thin-films were removed using a steel blade and collected in liquid nitrogen in a glass vial.
• the glass vial was capped with a rubber stopper with half open and transferred into a -80 ° C freezer (Thermo Fisher Scientific) for a temporary storage, and then transferred to a VirTis Advantage bench top tray lyophilizer with stopper recap function (The VirTis Company, Inc. Gardiner, NY). Lyophilization was performed over 60 h at pressures no more than 100 mTorr, while the shelf temperature was gradually ramped from -40°C to 25°C. The lyophilization cycle is shown in Table 24.
• the aerosol performance properties of the thin-film freeze-dried plasmid powder samples were determined as previously described (Li et al, 2015; Sahakijpijam et al, 2020a; Moon et al, 2019; Sahakijpijam et al, 2020b). Briefly, a Next Generation Pharmaceutical Impactor (NGI) (MSP Corp, Shoreview, MN) connected to a High-Capacity Pump (model HCP5, Copley Scientific, Nottingham, UK) and a Critical Flow Controller (model TPK 2000, Copley Scientific, Nottingham, UK) was adopted to assess the aerosol performance.
• NKI Next Generation Pharmaceutical Impactor
• Plasmid DNA powder (2-3 mg) was loaded into a Size #3 capsule, and the capsule was loaded into a high-resistance Plastiape® RS00 inhaler (Plastiape S.p.A, Osnago, Italy) attached to a United States Pharmacopeia (USP) induction port (Copley Scientific, Nottingham, UK). The powder was dispersed to the NGI at the flow rate of 60 L/min for 4 s per each actuation, providing a 4 kPa pressure drop across the device.
• the deposited powders from the capsule, inhaler, adapter, induction port, stages 1-7, and the micro-orifice collector (MOC) were collected by diluting with water, and the amount of plasmid DNA deposited was quantified using a PicoGreenTM dsDNA Assay Kit following manufacturer’s instruction.
• the Copley Inhaler Testing Data Analysis Software (CITDAS) Version 3.10 was used to calculate the mass median aerodynamic diameter (MMAD), the geometric standard deviation (GSD), and the fine particle fraction (FPF).
• MMAD mass median aerodynamic diameter
• GSD geometric standard deviation
• FPF fine particle fraction
• the FPF of delivered dose was calculated as the total amount of plasmids collected with an aerodynamic diameter below 5 pm as a percentage of the total amount plasmids deposited on the adapter, the induction port, stages 1-7 and MOC. v. Scanning electron microscopy (SEM)
• Plasmid pCMV-b was formulated into Formulation P7 (Table 23) and thin-film freeze-dried. The dry powder was then reconstituted and then digested with EcoR I or Hind III and EcoR I for 2 hours and applied to agarose gel (0.8%) for electrophoresis. Controls include pCVM-b alone or pCMV-b in Formulation P7 without thin-film freeze- drying, both digested and applied to electrophoresis.
• DNA dry powders are shown in FIG. 52 and Table 25. It is clear that dry powders prepared with lower solid contents showed better aerosol performance.
• the FPF ⁇ 5 ⁇ m (of the recovered dose) of plasmid formulations prepared with 1.0, 0.5 and 0.25%, w/v, of solid content (PI, P4 and P3) were 32.92 ⁇ 2.52%, 34.55 ⁇ 2.34% and 55.13 ⁇ 2.36%, , respectively, and the MMAD values of these powders were 1.58 ⁇ 0.07 pm, 1.77 ⁇ 0.22 pm and 1.44 + 0.16 pm, respectively (Table 25).
• the effect of the plasmid loading plasmid vs.
• Formulation 7 has 5% plasmid DNA loading, contains TE, and have overall good aerosol performance properties. This formulation was chosen to test the integrity of the plasmid DNA after it was subjected to TFFD and reconstitution. Plasmid pCMV-b was formulated to Formulation 7 and thin-film freeze-dried. It was then reconstituted, digested with EcoR I or Hind III and EcoR I for 2 hours and applied to agrose gel for electrophoresis. Controls include pCVM-b alone or pCMV-b in Formulation 7 without thin-film freeze-drying, digested and applied to electrophoresis. As shown in FIG. 54, subjecting pCMV-b to TFFD did not cause any significant change in the plasmid integrity.
• Example 6 Thin-Film Freezing and Thin-Film Freeze-Drying of mRNA-LNPs A. Preparation of TFF-mRNA/LNP dry powder
• Formulation 1 To a scintillation vial, 3.5 mL of poloxamer 188 (1.0 mg/mL) was added, followed by the addition 10.0 mL of a mRNA COVID-19 vaccine that has received emergency use authorization (diluted, 2.567 mg LNP/mL). The mixture was gently shaken and dropped dropwise onto the cryogenically cooled (-180°C) stainless steel drum. The frozen sample was collected in a stainless-steel container, filled with liquid nitrogen. The sample was transferred in a glass lyophilized vial and stored in a -80°C freezer until placing in a lyophilizer.
• the solvent was removed by lyophilizer by a processing of holding at —40 °C for 20h at or below lOOmTorr, ramping to 25°C for 20h at lOOmTorr, and holding at 25 °C for 5h at lOOmTorr.
• the dry nitrogen gas was backfilled, and the lid of the vial was closed by the stoppering system before open the lyophilizer door.
• the vial was sealed with an aluminum cap for storage.
• Formulation 2 To a scintillation vial, 10.5 mL of sucrose (20.0 mg/mL) and 4.2 mL of poloxamer 188 (1.0 mg/mL) were added, followed by the addition of 3.0 mL of a mRNA COVID-19 vaccine (diluted, 2.567 mg LNP/mL). The mixture was gently shaken and dropped dropwise onto the cryogenically cooled (-180°C) stainless steel drum. The frozen sample was collected in a stainless-steel container, filled with liquid nitrogen. The sample was transferred in a glass lyophilized vial and stored in a -80°C freezer until placing in a lyophilizer.
• the solvent was removed by lyophilizer by a processing of holding at —40 °C for 20h at or below lOOmTorr, ramping to 25°C for 20h at lOOmTorr, and holding at 25°C for 5h at lOOmTorr.
• the dry nitrogen gas was backfilled, and the lid of the vial was closed by the stoppering system before open the lyophilizer door.
• the vial was sealed with an aluminum cap for storage.
• Formulation 3 To a scintillation vial, 8.0 mL of trehalose (20.0 mg/mL) and 4.6 mL of poloxamer 188 (1.0 mg/mL) were added, followed by the addition of 2.0 mL of a mRNA COVID-19 vaccine (diluted and dialyzed to remove excipients, 2.127 mg LNP/mL). The mixture was gently shaken and dropped dropwise onto the cryogenically cooled (-180°C) stainless steel drum. The frozen sample was collected in a stainless-steel container, filled with liquid nitrogen. The sample was transferred in a glass lyophilized vial and stored in a -80°C freezer until placing in a lyophilizer.
• the solvent was removed by lyophilizer by a processing of holding at -40°C for 20h at or below lOOmTorr, ramping to 25°C for 20h at lOOmTorr, and holding at 25°C for 5h at lOOmTorr.
• the dry nitrogen gas was backfilled, and the lid of the vial was closed by the stoppering system before open the lyophilizer door.
• the vial was sealed with an aluminum cap for storage.
• Formulation 4 To a scintillation vial, 8.0 mL of sucrose (20.0 mg/mL) and 4.6 mL of poloxamer 188 (1.0 mg/mL) were added, followed by the addition of 2.0 mL of a mRNA COVID-19 vaccine (diluted and dialyzed to remove excipients, 2.127 mg LNP/mL). The mixture was gently shaken and dropped drop wise onto the cryogenically cooled (-180°C) stainless steel drum. The frozen sample was collected in a stainless-steel container, filled with liquid nitrogen. The sample was transferred in a glass lyophilized vial and stored in a -80°C freezer until placing in a lyophilizer.
• the solvent was removed by lyophilizer by a processing of holding at -40°C for 20h at or below lOOmTorr, ramping to 25 °C for 20h at lOOmTorr, and holding at 25 °C for 5h at lOOmTorr.
• the dry nitrogen gas was backfilled, and the lid of the vial was closed by the stoppering system before open the lyophilizer door.
• the vial was sealed with an aluminum cap for storage.
• Formulation 5 To a 200 ⁇ L centrifuge tube, 40 ⁇ L of sucrose (20.0 mg/mL) and 13 ⁇ L of poloxamer 188 (1.0 mg/mL) were added, followed by the addition of 10 ⁇ L of a mRNA COVID-19 vaccine (diluted and dialyzed to remove excipients, 2.16 mg LNP/mL). The mixture was gently shaken and dropped drop wise onto the cryogenically cooled (-180°C) stainless steel drum. The frozen sample was collected in a stainless-steel container, filled with liquid nitrogen. The sample was transferred in a glass lyophilized vial and stored in a -80°C freezer until placing in a lyophilizer.
• the solvent was removed by lyophilizer by a processing of holding at -40°C for 20h at or below lOOmTorr, ramping to 25°C for 20h at lOOmTorr, and holding at 25°C for 5h at lOOmTorr.
• the dry nitrogen gas was backfilled, and the lid of the vial was closed by the stoppering system before open the lyophilizer door.
• the vial was sealed with an aluminum cap for storage.
• shelf freeze-drying For mRNA-LNP formulations 1, 2, and the original mRNA COVID vaccine upon dilution as mentioned above, dry powders were also prepared with conventional shelf freeze-drying.
• the mRNA-LNPs in suspension (0.6 mL) were placed into 2 mL lyophilized vials and the vials were placed in an Advantage EL shelf freeze dryer.
• the shelf temperature was cooled from room temperature to -50°C at the rate of l°C/min and maintained at 50°C for lh before drying.
• the drying cycle was the same as one used to sublime water from the thin-film frozen samples.
• the approved mRNA COVID vaccines were dialyzed against at least 1,000 fold-volume of diethyl pyrocarbonate (DEPC)-treated water at 4 °C for 24 h. The concentration of LNPs was then adjusted based on the volume change after dialysis.
• DEPC diethyl pyrocarbonate
• 1.200 mL of the approved mRNA COVID vaccine was placed into a dialysis tube (Spectrum, Stamford, CT), then the dialysis tube was placed in 1,500 mL of DEPC-treated water in an external beaker with a gentle stirring speed of 100 rpm at 4°C for 24 h.
• the dialysis solution (DEPC-treated water) was changed every 8 h.
• 1.398 mL of sample was recovered from the dialysis tube.
• the concentration of LNPs was calculated based on the volume change for the formulation preparation for TFF.
• TFF powder was placed into a disposable UV cuvette and reconstituted with filtered water (Evoqua, Warrendale, PA). Particle size distribution was measured using a Zetasizer Nano ZS (Malvern Panalytical Ltd, Malvern, UK) with dispersant refractive index of 1.33 and material refractive index of 1.45. Shown in Table 1 below are the particle size (Z-average) of the mRNA-LNPs before they were subjected to thin-film freezedrying (TFFD), after they were subjected to TFFD and reconstitution, and after the dry powders were storated at in a refrigerator ( ⁇ 4°C) or at temperature ( ⁇ 25°C) for three weeks.
• TFFD thin-film freezedrying
• mRNA loading in a mRNA/LNP COVID vaccine formulation was quantified using a Quanti-iT RiboGreen assay kit (Invitrogen, Carlsbad, CA) as previously described (Blakney et al., 2019; Yang et al, 2020). Powder samples were reconstituted to the same concentration as the liquid formulations before TFF process. All samples were diluted two, twenty, two-hundred, and two-thousand times in 1 x TE buffer (RNase-free) containing 0.5% (v/v) Triton X-100 (Sigma Aldrich, St. Louis, MO) for a 15 min of incubation to detect total mRNA.
• 1 x TE buffer RNase-free
• Triton X-100 Sigma Aldrich, St. Louis, MO
• Encapsulation efficiency Table 2 Encapsulation efficiency iii. Transmission Electron Microscope (TEM) Analysis
• TEM Transmission Electron Microscope
• the morphology of LNP formulations was studied using FEI Tecnai transmission electron microscopy. Thin-film freeze-dried mRNA/LNP powder was reconstituted in water and diluted with purified water to obtain an LNP concentration of 0.1- 0.3 mg/mL. Five ⁇ L of LNP dispersion was added on a 200-mesh carbon film, copper grid (Electron Microscopy Sciences, Hatfield, PA). After one minute, a filter paper was used to gently remove the liquid from the edge of the grid. Five ⁇ L of 1% phosphotungstic acid was dropped on the grid to negatively stain the sample. After one minute, a filter paper was used to remove the stain from the edge of the grid. The sample was air-dried before capturing images. See FIG. 55.
• Patil-Gadhe and Pokharkar Int. J. Pharm., 501(1-2): 199-210, 2016. Patlolla et al., J. Control. Release, 144(2):233-241, 2010.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Pulmonology (AREA)
• Biophysics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Otolaryngology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Botany (AREA)
• Biochemistry (AREA)
• Physics & Mathematics (AREA)
• Biomedical Technology (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=75888214

Family Applications (1)

Country Status (9)

Cited By (3)

Families Citing this family (7)

Citations (41)

Family Cites Families (1)

• 2021
  • 2021-04-20 WO PCT/US2021/028140 patent/WO2021216541A1/en unknown
  • 2021-04-20 CN CN202180047291.8A patent/CN115996707A/zh active Pending
  • 2021-04-20 US US17/235,771 patent/US20220023204A1/en active Pending
  • 2021-04-20 JP JP2022563375A patent/JP2023522103A/ja active Pending
  • 2021-04-20 KR KR1020227040575A patent/KR20230005244A/ko active Search and Examination
  • 2021-04-20 CA CA3175301A patent/CA3175301A1/en active Pending
  • 2021-04-20 IL IL297450A patent/IL297450A/en unknown
  • 2021-04-20 AU AU2021260578A patent/AU2021260578A1/en active Pending
  • 2021-04-20 EP EP21724891.3A patent/EP4138791A1/en active Pending

Patent Citations (45)

Non-Patent Citations (52)

Also Published As

Similar Documents

Legal Events